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ABSTRACT
Breast Cancer (BC) is the most frequently diagnosed cancer; 1:8 women are at risk of
developing BC in her lifetime. Cancer metastasis causes the majority of deaths in BC patients.
Moreover, side effects of traditional chemotherapeutic drugs (TCD) impair the quality of life of
these patients. Discovery and development of safe and effective new therapies is imperative for
the treatment of BC and targeting metastasis. The goal herein is to further expand the applicability
of transgenic zebrafish for in vivo xenotransplantation of human BC cells and to screen potential
chemotherapeutics for toxicity and efficacy. For xenotransplantation, MCF-7, BT-474, and MDAMB-231 BC cells were used to canvas the benign and malignant types of BC, respectively.
Fluorescently-labeled MCF-7, BT-474, and MDA-MB-231 cells and the cytotoxic effect of TCD
(doxorubicin, 4-hydroxytamoxifen, and paclitaxel) were determined for validation in vitro using
cell viability assay. Test compounds (extracts of Tinospora crispa and potent microtubule
inhibitors) were used to determine the cytotoxicity in vitro. Maximally tolerated concentration and
no observed adverse effect level (NOAEL) of were determined in zebrafish following a waterborne
exposure to concentrations (1-50 µM) of doxorubicin, 4-hydroxytamoxifen, paclitaxel, and
curcumin and (10-800 nM) mertansine, ansamitocin P-3, and monomethyl auristatin E (MMAE)
over 96 hours. NOAELs for paclitaxel, mertansine, ansamitocin P-3, and MMAE were 25, 400,
ii

50, and 400 nM, respectively. Zebrafish were xenotransplanted with MCF-7, BT-474, and MDAMB-231 cell lines to observe the effects of exposure to microtubule inhibitors on the proliferation
of cancer cells. After xenotransplanting 50-100 BC cells/larva at 2 days post-fertilization, cell
growth and migration were imaged at 1 and 5 days post-injection using fluorescent microscopy.
Paclitaxel (25nM) significantly reduced the proliferation of MCF-7 cell xenografts compared to
controls, confirming the use of this model for MCF-7 cell xenografts. Mertansine (10 and 200 nM)
also significantly reduced the proliferation of MCF-7 cells. To our knowledge, this is the first study
that used paclitaxel in BC xenografts even though it is a widely used chemotherapeutic in the
treatment of BC. Additionally, NOAEL in vivo and cytotoxic effects of mertansine in zebrafish
xenografts have not been studied before.
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CHAPTER I
INTRODUCTION
1.1 Breast Cancer
Breast cancer (BC) is the most frequently diagnosed cancer and represents 25% of all
cancers detected in women worldwide. According to the American Cancer Society, it is estimated
that approximately 266,120 women will be diagnosed, and over 41,400 women are estimated to
succumb to this disease in the United States in 2018. One in eight women is at a risk of developing
BC in her lifetime (Siegel et al., 2018). BC incidence rose from 1980s and declined in early 2000s.
The five-year survival rates have increased from 75% to over 90% from 1975 to 2011.
Considerable progress has been made in the last several decades in the treatment of BC with the
identification of breast cancer intrinsic subtypes. Leading to a change in classification from ductal,
inflammatory or invasive to expression of molecular features from a biopsy for estrogen receptor
(ER), progesterone receptor (PR), and the human epidermal growth receptor 2 (HER2) protein.
BC is classified on the basis of molecular signatures as ER positive (ER+), PR positive (PR+), or
HER2 protein positive (HER2+). Approximately 70% of BC is ER/PR+, and 20% of BC is
HER2+. BC can be positive for two or three receptors at a time or it can be negative for all three.
This latter scenario is known as triple negative BC (TNBC) (Perou et al. 2000). ER/PR+ BC is
responsive to treatment with tamoxifen (TAM), HER2 protein positive BC is amenable to
treatment with Trastuzumab, and therapy options for TNBC are limited to traditional
1

chemotherapy. Doxorubicin (DOX) and paclitaxel (PTX) are also used to treat later stage and more
aggressive ER+ and HER2+ BC, and thus are applicable to all cases of BC (Ades et al., 2017). The
poor prognosis of breast cancer is due to the subsequent formation of metastasis in approximately
30-50% of patients even when they are treated with chemotherapy and endocrine adjuvant
therapies at early stages of BC (Lin 2013; Roche and Vahdat 2011; Martin et al. 2017).

Metastasis
Metastasis is the spread of breast cancer to other locations in the body and is a highly
dynamic process (Mansel et al. 2007). Majority of the deaths in breast cancer patients are due to
the metastasis to different organs, and not the primary tumor itself (Weigelt et al. 2005). Metastatic
BC is also classified as stage IV breast cancer and patients suffering from stage IV BC have similar
treatment options available as other stages of BC. Currently, there are no therapeutic agents for
the prevention of metastasis and BC is considered incurable once it reaches a metastatic stage. The
approaches for treating metastatic cancer are palliative in nature (Roche and Vahdat 2011).
The link between motility of the cancer cells and the development of metastasis was first
suggested by Rudolf Virchow, a German scientist (David 1988). The BC metastasis process, as
reviewed by Scully et al., involves multiple sequential steps and tumor cells must complete all
these steps for successful metastasis (Scully et al. 2012). Metastasis initially occurs by invasion
into surrounding host tissue. The tumor cells disrupt the cell-to-cell adhesions and cell adhesion to
extracellular matrix (ECM). Cell-to-cell adhesion is largely mediated by the cadherin family and
in BC metastasis (Li and Feng 2011). Integrins, transmembrane receptors on the components of
ECM, are responsible for the adherence of tumor cells to ECM (Mego et al., 2010). Transport of
2

tumors from the primary tumor site to distal organs occurs at a single-cell level or collectively in
a number of cells after intravasation into the blood circulation or lymphatic vessels (McSherry et
al. 2007). The collective migration occurs in intermediately or highly differentiated lobular
carcinomas of the breast. However, in poorly differentiated tumors, due to abnormalities in the
structure and function of the intercellular adhesion proteins, the coordinated cell migration may
change to single cell migration. The presence of intercellular junctions is vital for the collective
migration of cancer cells; hence they circulate as emboli in the blood or lymphatic vessels after
invasion (McSherry et al. 2007). The tumor cells then endure cell cycle arrest and adhere to
capillary beds in the target organs, occasionally for long periods of time, before tumor cells
extravasate the parenchyma of the target organ whereby they proliferate and develop angiogenesis
(Hunter et al., 2008). It is critical that the tumor cells simultaneously evade immunosurveillance
and apoptosis to survive as tumor cells are undergoing these steps (Fidler, et al., 1978; Hunter et
al., 2008). Metastasis cannot occur until there is a favorable microenvironment making tumor
microenvironment a critical factor for this process (Scully et al. 2012).
Novel anti-cancer drugs are rarely used in metastatic cancer settings, which is a challenge
in clinical settings as drug candidates are tested in patients with metastatic disease. Neoadjuvant
therapies in patients with localized cancer are being evaluated to prevent cancer metastasis; to
determine if the neoadjuvant therapies are helpful in eliminating the disseminated cancer cells
which lead to formation of metastases. Therefore, for novel anti-cancer drug discovery, it is
important to simulate conditions which promote the normal proliferation and migration of cancer
cells for a robust and efficient model. The established in vitro models must have in vivo
complements in order to gain insights in the molecular mechanisms as well as to elucidate
3

multicellular interactions involved with tumor progression (Vittori et al. 2015). Mouse models are
traditionally used for screening anti-cancer compounds but have certain disadvantages that limit
their use to study metastasis. It is difficult to assess early stage metastasis, the metastatic process
is a long process in mice, and sacrificing the animal is essential to study tumor lesions (Zhao et al.
2015). Although it is difficult to simulate the metastatic process entirely in zebrafish, certain stages
of metastasis can be studied. It was observed that tumorigenic human gastrointestinal cells
metastasize when xenotransplanted in zebrafish and non-tumorigenic tissues do not metastasize
(Marques et al. 2009). The clinical behavior of tumor cells is also conserved in zebrafish as
demonstrated by glioblastoma cells injected in the brain and yolk sac which did not metastasize
beyond the surrounding brain tissue (Lal et al. 2012). The transgenic zebrafish, being transparent,
affords us the opportunity to study tumor metastasis in vivo using high resolution microscopy, and
to observe the in vivo growth patterns of human cancer cell lines in terms of invasiveness and
response to cytotoxic compounds. Moreover, in zebrafish, the rapid process of metastasis can be
observed in as soon as two days post injection (Yang et al. 2013). Using targeted disruption of
proteins and molecules, inhibition of metastasis can be studied in zebrafish. For example,
inhibition of PDK1/PLCy1 complex using 2-O-Bn-InsP5, a small molecule inhibitor, reduced the
metastasis of MDA-MB-231 BC cells in 2 dpf zebrafish embryos. The zebrafish embryos were
injected at different sites including duct of Cuvier and perivitelline cavity, and significantly
reduced dissemination of tumor cells was observed as compared to controls (Raimondi et al. 2016).
Similar significant reduction in dissemination of MDA-MB-231 cells was also seen when vintegrin was knocked down in MDA-MB-231 and by chemically inhibiting v-integrin using
GLPG0187, suggesting the involvement of v-integrin in metastasis (Y. Li et al. 2015).
4

Tumor microenvironment
The presence of a conducive microenvironment for tumor cell proliferation and malignant
progression is critical for the development of metastases (Psaila et al. 2007). The tumor
microenvironment consists of fibroblasts, immune cells, mural cells of the blood and lymph
vessels, along with the ECM and endothelial cells, and the malignant cells interact with these cells
at the primary as well as the metastatic sites (Folkman and Kalluri 2004; Kalluri and Zeisberg
2006; Fidler et al. 2007). These multiple types of cells secrete cytokines, growth factors, and
proteases that may be involved in the invasion and metastasis of BC primary tumors (McSherry et
al. 2007). The transformation of “in situ” breast cancer to metastatic form is a result of these
interactions (Coghlin and Murray 2010). The metastatic cascade is complex, and this complexity
is attributed by the tumor cell biology as well as the entire organism in which the tumor dwells.
There is limited literature on the microenvironment in zebrafish, however it is possible to study
the key tumor microenvironment factors in a zebrafish xenograft model. The hematopoietic stem
cell niche is proposed to be a factor in housing cancer cells to bone marrow. The caudal
hematopoietic tissue in zebrafish is the area of embryonic hematopoiesis and thought to be
composed of a bone marrow hematopoietic stem cell niche. Sacco et el injected multiple myeloma
cells, fluorescently labeled, in the intracardiac region of 2 dpf Casper zebrafish and found tumor
cells localized in hematopoietic tissue within 30 minutes of injection (Sacco et al. 2016). Another
group injected multiple tumor cells in the duct of Cuvier found the cancer cells localized in the
caudal hematopoietic tissue area. They discovered a novel mechanism of formation of the
metastatic niche and that the site of formation of micrometastasis is determined by the
physiological migration of neutrophils, and an interplay between VEGF and neutrophils (He et al.
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2012). These studies point to the relevance of zebrafish in studying the role of hematopoietic niche
in metastasis. Zebrafish larvae provide the opportunity to observe the behavior of grafted tumor
cells by high resolution in vivo imaging techniques and rapid analysis of metastatic behavior of
human tumor cells (Tobia et al. 2013). Our goal is to employ the transgenic zebrafish
xenotransplantation model to identify cytotoxic compounds that can be used in the treatment of all
the BC subtypes.

Traditionally used chemotherapeutics
The available treatment options for BC include a) surgery, b) radiation therapy, c)
chemotherapy and d) targeted therapy to cell receptors. a) Surgery and b) radiation are invasive
methods and are more localized, but not feasible for metastasis treatment. The current gold
standard for treating early stage breast cancer patients is breast-conserving surgery (BCS) with
adjuvant radiotherapy (Franceschini et al. 2015). c) Chemotherapeutic drugs, on the other hand,
are potent cytotoxic agents with different mechanisms of action depending on the type of solid
tumor being treated. Tamoxifen (TAM), DOX, and PTX are the most widely used drugs depending
on the type of BC. DOX and TAM are the first line treatment for ER/PR+ BC, are associated with
marked toxicities and long-term adverse events such as lymphedema, neurotoxicity, and
chemotherapy induced peripheral neuropathy (CIPN) which impair the quality of life of these
patients (Hershman et al. 2011). For TNBC, there are no specific treatment options available to
deal with the metastasis, which is the main cause of death in the patients, as the metastasis spreads
and forms micrometastasis in bones and other organs. However, DOX along with daunorubicin is
the first line of treatment for patients suffering for this type of BC. As in other types of BC
subtypes, in TNBC patients as well, there is a development of resistance and they stop responding
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to the treatment (Ades, Tryfonidis, and Zardavas 2017) pointing to an urgent need for efficient
therapeutics with minimal side effects.
Tamoxifen (TAM) is the first line of treatment for ER/PR+ BC, a selective estrogen
receptor modulator (SERM), which acts as an antagonist for estrogen receptor in breast tissues
(Rivenbark et al. 2013). Tamoxifen, a nonsteroidal triphenylethylene derivative, is a competitive
inhibitor of estrogen binding at the ER and blocks estrogen action on the BC cells expressing these
receptors. Upon binding to the ER, tamoxifen induces the synthesis of cytosine transforming
growth factor-β (TGF-β) and inhibits the proliferation of these cells by negatively regulating the
autocrine system (V. C. Jordan 1993; Sawka et al. 1986). Although, with adjuvant therapy, a 35%
decrease in the BC is seen in patients treated with tamoxifen, patients develop resistance to
tamoxifen and stop responding to the treatment. Based on the findings of several trials of five years
of TAM treatment versus no treatment, TAM increased the incidence of endometrial cancer in
postmenopausal women who had not undergone hysterectomy before trial entry. The overall lifetable calculations for older women suggest in 15 years a 2-3% risk of endometrial cancer if they
used adjuvant TAM, and if they use TAM for 10 years that would put them at an additional risk
of 2% in 15 years. However, this risk is lower in premenopausal women (Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG) et al. 2011; Davies et al. 2013).
Doxorubicin (DOX) is an anthracycline drug extracted from Streptomyces peuceutius in
the 1970s and is a routinely used antineoplastic agent in the treatment of various cancers such as
breast, ovarian, lung, gastric, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma (Thorn et al.
2011). DOX acts mainly by intercalating the DNA and disrupting the topoisomerase-II-mediated
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DNA repair leading to DNA damage and cell death. Another proposed mechanism of action of
DOX is the formation of reactive oxygen species upon oxidation to semiquinone which gets
converted back to DOX leading to formation of free radicals which damage the DNA, proteins and
triggers apoptotic cell death pathways in cancer cells (Doroshow 1986; Gewirtz 1999). However,
the use of doxorubicin is limited by cardiotoxicity and doxorubicin resistance in patients (Thorn
et al. 2011). In most cancer treatments DOX is rarely administered in isolation but with other
chemotherapeutic compounds such as taxanes or trastuzumab. Moreover, co-treatment with
trastuzumab or taxanes also results in cardiotoxicity (Gianni et al., 2007). A combination of
taxanes and anthracyclines are now widely used as standard first line treatment in advanced stages
of breast cancer as this combination showed better response rates than standard anthracycline
based treatment (Ghersi et al. 2005).
Taxanes (paclitaxel and docetaxel) are widely used to treat breast cancer, especially the
metastatic anthracycline-resistant breast cancers. Taxanes are associated with adverse side effects
which include myalgias, peripheral neuropathy, and skin reactions. CIPN, a distal sensory
neuropathy, is marked by pain, numbness, tingling, and a decrease in the functional capacity in the
extremities. The other side effects associated with taxanes include ataxia, paresthesia, impairment
of joint position sense, and a loss in tendon function (Hershman et al. 2011; De Laurentiis et al.
2008). Randomized trials of taxanes as adjuvant therapy for breast cancer indicated a range of 1523% grade 2 and 3 neuropathy based on the NCI (National Cancer Institute) Common
Terminology Criteria. A grade 2 neuropathy results in mild symptoms affecting functioning
whereas grade 3 neuropathy greatly affects routine activities. A study conducted to evaluate the
prevalence and severity of symptoms after adjuvant paclitaxel treatment with median months since
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last treatment with PTX was 12 months was conducted in 50 women. The study found that 80%
of the patients who received taxane-based adjuvant chemotherapy for treatment of early stage
breast cancer experienced neuropathy symptoms up to 2 years after completing the treatment
(Hershman et al. 2011).
As patients with TNBC cannot be treated using hormone or targeted therapy, there are
limited treatment options and chemotherapy is the mainstay. Recent research has identified
potential new targets for breast cancer drugs. There are five major areas where targeted therapies
are being extensively studied: a) monoclonal antibodies, b) tyrosine kinase receptor inhibitors, c)
small molecules targeting molecule-drug conjugates, d) antisense and siRNA approaches, and e)
antibody drug conjugates (ADCs). These drugs are currently being evaluated in the treatment of
TNBC as single or combination therapy to discover and develop effective therapies for improving
the rate of survival, and the quality of life of patients during cancer treatment and post-cancer.

Trends in breast cancer drug discovery:
Targeted therapies aim molecular targets and pathways which are vital for cancer cell
proliferation. These may be VEGF (vascular endothelial growth factor), tyrosine kinases,
epidermal growth factor receptor (EGFR), androgen receptor, poly (ADP-ribose) polymerase
(PARP). By targeting these molecular targets and pathways that the cancer cells depend on to
proliferate and metastasize, researchers have been able to identify and develop compounds that
cause selective cytotoxicity in cancer cells with minimized damage to host cells (Nagini 2017).
The other aspect of targeted therapies is to explore natural products to identify potent anti-cancer
compounds. However, effectiveness of novel anti-cancer compounds is limited by a lack of
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selectivity for tumor cells, and potent anti-cancer compounds need to be used close to their
maximally tolerated dose (MTD) to achieve a therapeutic effect that is clinically effective. In many
cancer types, a standard modality is to administer a combination of drugs which have different
mechanisms of action as well as their toxicity profiles do not overlap, thereby improving antitumor
activity by exhibiting an additive or synergistic anti-cancer effect (Chari et al. 2014). However,
such regimens render systemic toxicity in the patient and are effective only a small proportion of
cancers. To overcome the issue of limited clinical efficacy, antibody drug conjugates (ADC’s)
were developed. ADC’s combine two approaches of targeted therapy- identification of specific
molecular markers expressed by tumor cells called antigens, using antibodies that target the
antigens as vehicles for selective drug delivery to the tumor cell, and linking the cytotoxic drug to
the cytotoxic drug without causing chemotherapeutic damage to non-target tissues (Doronina et
al. 2003; Chari et al. 2014).

Antibody Drug Conjugates (ADC)
Antibody drug conjugates comprise mainly of three components a) antibody, b) linker, and
c) cytotoxic drug or payload as shown in Figure 1.
Antibody- Monoclonal antibodies have been used as targeted therapies in cancer because
cancer cells express specific molecular markers such as CD33 on malignant blast cells in patients
suffering from acute myeloid leukemia (Linenberger 2005), CD30 positive Hodgkin/ReedSteinberg cells in Hodgkin lymphoma and CD30 positive large anaplastic lymphoid cells in
systemic anaplastic large cell lymphoma (ALCL) (van de Donk and Dhimolea 2012), and HER2
positive breast cancer cells (Gutierrez and Schiff 2011) are responsible for the progression and
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survival of the tumor cells. These tumor-associated antigens should be minimally expressed by
normal human tissues. The antibody should be well internalized by receptor-mediated endocytosis
and the target antigen should not be downregulated by the ADC (Perez et al. 2014; Panowski et al.
2014). The rate of internalization of the ADC in the cancer cell is a poorly understood process and
is affected by factors like epitope on the target antigen, high interstitial tumor pressure,
downregulation of the antigen, and presence of kinetic and physical barriers that diminish the
cytotoxic payload uptake (Mack et al. 2014; Perez et al. 2014). The antibodies used can be human,
humanized, and chimeric or mouse. However, the most commonly used antibodies include human
IGg isotypes. Once part of the ADC, the antibodies can retain their original properties and activate
immune functions and still act as signal modulators or receptor inhibitors (Xie et al. 2004).
Currently, there are four approved ADC’s for cancer treatment which are gemtuzumab ozogamicin
(anti-CD33), brentuximab vedotin (anti-CD30), trastuzumab emtansine (anti-HER2), inotozuman
ozogamicin

(anti-CD22)

for

acute

myelogenous

leukemia,

anaplastic

large

cell

lymphoma/Hodgkin’s lymphoma, HER2+ breast cancer, and acute lymphoblastic leukemia
respectively (Doronina et al. 2003; Gualberto 2012; Dhillon 2014).
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Figure 1: Components of an antibody drug conjugate (ADC).
Linker- The pharmacokinetics, therapeutic index, and efficacy of the ADC is dependent
on the linkers. Ideally, a linker should be stable and prevent the release of the cytotoxic drug before
reaching the target, thus preventing off-target toxicity. The linker should be able to release the
drug once the ADC is internalized. The drug-antibody ratio (DAR) is also critical because
attaching too few drug molecules may lead to a decrease in the efficacy and attaching too many
drug molecules may make the ADC unstable. This may lead to altered pharmacokinetics, increased
plasma clearance, reduced half-life that leads to an increased systemic toxicity (Perez et al., 2014).
Currently, the licensed ADCs are produced with nonspecific conjugation to lysine residues and
non-canonical amino acid incorporation or modification of peptide tags (Zhou, 2017). Linkers may
be cleavable or non-cleavable. Cleavable linkers (acid sensitive, lysosomal protease-sensitive, or
glutathione-sensitive) increase the possibility of bystander effect (Panowski et al., 2014). For
screening different antibodies and linkers for the ADC’s, it is important to consider the difference
in pharmacodynamics and pharmacokinetics when the ADC exposure is waterborne. This also
applies to solubility of compounds in DMSO or other suitable solvents for waterborne exposures
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and the concentration of these solvents as hydrophobic compounds or high molecular weight
compounds cannot be administered in a waterborne exposure.
Drug or cytotoxic payload: There are two classes of compounds being extensively used
in the design of payloads, and these compounds and their derivatives are being studied as ADC in
a number of clinical trials for various solid and liquid tumors. The two classes of compounds are
microtubule inhibitors and DNA intercalators. The first generation of ADCs used classical
chemotherapy drugs like doxorubicin and methotrexate and offered the benefit of well-known
cytotoxic profile. Studies showed that the actual concentration of the cytotoxic payload in the
tumor cells was minimal with only 1-2% of the administered dose reaching the tumor cells.
Therefore, the cytotoxic payload used must be highly potent and effective at nanomolar and
picomolar concentrations (Teicher and Chari, 2011). Since then, extensive research has been
conducted in the design and selection of payloads, antibodies, and linkers. To optimize the
therapeutic index of the drug, tumor selectivity is improved to either increase the maximally
tolerated dose (MTD) or to increase the potency of the cytotoxic drug thereby decreasing the
minimum effective dose (MED)(Chari et al. 2014).

Microtubule inhibitors as payloads:
Major dynamic structural component of a cell that is vital in the development, reproduction,
division, and in maintaining the shape of the cell, microtubules are polymers of α and β tubulin
heterodimers. Microtubules exhibit complex polymerization dynamics which determine and
regulate their biological functions. The microtubules are polymerized by a mechanism known as
nucleation-elongation wherein a short microtubule nucleus is formed followed by lengthening of
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the microtubule at each end with a reversible and noncovalent addition of tubulin dimers (Jordan,
2002). The complex polymerization dynamics are possible with the binding of tubulin to guanine
triphosphate (GTP) whereby energy is released by hydrolysis of (GTP) to guanine diphosphate
(GDP) and Pi at the growing end of microtubules, leaving a microtubule core consisting of tubulin
with stoichiometrically bound GDP. Until the tubulin subunit dissociates from the microtubule,
GDP remains non-dissociable and non-exchangeable. There are two dynamic behaviors of
microtubules, “treadmilling” and “dynamic instability”. In treadmilling, there is a net growth of
one end of the microtubule and a net shortening of the other end. Dynamic instability involves
switching of phases between rapid growth and shortening of the microtubule ends, and these
transitions are regulated by the presence or absence of the region of tubulin-GDP at the
microtubule end. Growth of a microtubule continues as long as it maintains a stabilizing cap of
tubulin-GTP or tubulin-GDP-Pi at its end, and the loss of this cap results in depolymerization of
the microtubule (Jordan et al., 1993; Wilson and Jordan, 1995). Microtubule ends, known as plus
and minus ends, are not equivalent. The plus end is kinetically more dynamic than the minus end.
Both ends can elongate or shorten, but changes in length at the plus end are much larger than the
minus end. Microtubules endure lengthy periods of slow lengthening, short periods of quick
shortening, and periods of pause. Both treadmilling and dynamic instability occur in living cells
and are excellently regulated by microtubule associated proteins (MAP) and by drugs (Wilson and
Jordan, 1995). Microtubules are believed to be a major target for anti-cancer drug discovery
(Wilson and Jordan, 1995; Jordan et al., 1998; Pasquier and Kavallaris, 2008) and compounds that
target microtubules, microtubule stabilizers and destabilizers, are widely investigated in anticancer drug discovery (Pasquier and Kavallaris, 2008).
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Microtubule inhibitors
Taxol, a mitotic inhibitor, was isolated from the bark of Taxus brevifolia (northwest Pacific
Yew Tree) in 1967. It is produced by a fungal endophyte when grown on semisynthetic media,
first isolated from the phloem tissue of the Pacific Yew Tree (Stierle, Strobel and Stierle, 1993).
Bristol-Myers Squibb commercially developed this fungal endophyte under the trademark Taxol
and generic name Paclitaxel (PTX). PTX arrests cells by stabilizing spindle microtubules during
mitosis (Schiff and Horwitz, 1980; Wilson and Jordan, 1995). PTX has high affinity for
microtubules, leads to an increase in microtubule polymerization in vitro, boosts both nucleation
and elongation phases, and it decreases critical tubulin subunit concentration. PTX polymerized
microtubules are very stable and resist depolymerization by lower temperatures (4 °C) and
calcium, induces self-assembly of tubulin into microtubules at 0 °C in the absence of GTP, MAP’s,
and at alkaline pH (Aparajitha and Priyadarshini K, 2012). Although PTX is potent
chemotherapeutic drug, multidrug resistance developed by tumor cells and restricted drug access
to the growing tumor cells caused by immune vascularization, tissue hypoxia, reduction in blood
flow are limitations to tumor responsiveness (Vredenburg et al., 2001). Targeted therapies to
overcome these limitations are required which can utilize existing potent drugs and their
derivatives for effective anti-cancer activity.
Maytansinoids and auristatins are two largest classes of potent microtubule inhibitors
which are presently utilized as a “payload” of ADC’s in clinical trials (Beck et al., 2017). We
selected three compounds belonging to the microtubule inhibitor class- maytansinoids and
auristatins to test their maximally tolerated concentration in vivo, and their effect on BC cell
proliferation. These compounds are highly potent and reported IC50 values in various solid tumors
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is in the picomolar and nanomolar ranges.

Monomethyl auristatin e (MMAE)

Mertansine

Ansamitocin P-3

Figure 2: Chemical structures of monomethyl auristatin e (MMAE), ansamitocin P-3, and
mertansine.
Dolastatin 10, a linear peptide, was isolated from Dolabella auricularia, a shell-less marine
mollusk found in the Indian Ocean. Dolastatin 10 and its derivatives are microtubule inhibitors
and inhibit the binding of tubulin-GTP, causing a blockage of microtubule dynamics (Pettit et al.
1998). Auristatins, fully synthetic analogues of dolastatin 10, were identified by SAR studies based
on dolastatin 10 (Otani et al., 2000). Auristatins block the assembly of tubulin and cause a cell
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cycle arrest in the G2/M phase. They are a commonly used cytotoxic payload and comprise of the
majority of payloads in ADCs being investigated. For our studies, we selected monomethyl
auristatin e (MMAE), Figure 2, to determine the MTC in larvae over a period of 96 hours.
Bretuximab vedotin is an approved ADC for the treatment of anaplastic large cell
lymphoma/Hodgkin’s lymphoma.
Maytansinoids are another class of potent tubulin inhibitors. They are isolated from the
Ethiopian shrub Maytenus ovatus by Kupchan et al. in 1972 (Kupchan et al., 1972). Maytansine
was one of the first compounds found to kill cancer cells with IC50 values in the picomolar range
and was found to be more cytotoxic than doxorubicin, methotrexate, and 5-fluorouracil.
Maytansine attaches to tubulin with high affinity for tubulin located at microtubule ends. The
binding of maytansine to tubulin leads to cytological changes in which chromosomes are scattered
at random in the arrested cells in metaphase and leads to the formation of multinucleated or large
cells (Cassady et al., 2004). Maytansine inhibits microtubule assembly by binding to tubulin and
have KD~ 1µmol/L. Mertansine is a semisynthetic analog of maytansine (Kupchan et al., 1972),
small molecular weight of 737.5 Da cytotoxic agent (Xie et al., 2004). The intercellular target of
mertansine is tubulin, and it inhibits the polymerization of tubulin in cancer cells (Xie et al., 2004).

Natural products as anti-cancer compounds
Natural products continue to play a highly significant role in drug discovery and
development process. Natural compounds have a long and successful history in anticancer drug
discovery (Newman and Cragg, 2012). Natural products, owing to their chemical diversity and
biological activities, are attractive candidates for anticancer drug discovery. The National Center
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for Natural Products Research at The University of Mississippi is one of the largest natural product
research institutions in the country and has an extensive library of novel compounds isolated from
plants and other natural sources. Our initial approach was to test novel compounds with unknown
anti-cancer activity to develop this model as a medium-throughput anti-cancer drug screening tool.

Tinospora crispa
Tinospora crispa is a herbaceous vine found in Asian and African rainforests and mixed
deciduous forests (Pathak et al. 1995). Traditionally, this medicinal plant has found use as folk
prescription in Asian countries like Malaysia, Indonesia, Thailand, and the Philippines for treating
hypertension, diabetes, urinary disorders, fever, malaria, internal inflammation, rheumatism,
appetite stimulation, and maintaining good health (Kongsaktrakoon et al.1984) (Rahman et al.,
1999) (Pathak et al. 1995). Phytochemically, T. crispa is composed of diverse secondary
metabolites. More than 65 compounds have been isolated and identified such as alkaloids,
flavonoids, and flavone glycosides, lactones, sterols, triterpenes, diterpenes and diterpene
glycosides, and nucleosides. Clerodane-type furanoditerpenoids are the characteristic compounds
of T. crispa (Ahmad et al. 2016). Borapetoside A, borapetoside B, borapetol A, borapetol B,
tinoturbride, tinocrisposide, N-formylanondine, N-formylnornuciferine, N-acetyl nornuciferine
and picrotein are some of the chemical constituents isolated from T. crispa (Pathak et al. 1995).
Investigative studies have been performed by different groups of researchers to identify the active
constituents of T. crispa extracts responsible for diverse activities such as anti-inflammatory, antidiabetic, and anti-cancer activity as described below.
Abood et. al. evaluated crude ethanol extracts of T. crispa along with its isolated fractions
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for potential anti-inflammatory activity and observed that the ethanolic extract and its subsequent
fractions stimulated the murine macrophages from blood (RAW264.7) proliferation in a dose
dependent manner. The ethanol extract and its fractions increased RAW264.7 at a dose of 25-800
µg/mL, and improved intracellular expressions of cytokine INF-Υ, IL-6, and IL-8. The ethyl
acetate fraction was found to be the most active of all the fractions tested, with significant increase
in intracellular expression of cytokines in RAW264.7 macrophages (Abood, Fahmi and Abdulla,
2014). Methanolic and aqueous extracts of T. crispa stem reduced the secretion of macrophage
colony stimulating factor (M-CSF), vascular cell adhesion molecule (VCAM-1), and intracellular
cell adhesion molecule (ICAM-1) in TNF-α stimulated human umbilical vein endothelial cells
(HUVECs) (Kamarazaman, Amorn and Ali, 2012). T. crispa aqueous extract in doses of 50, 100,
and 150 mg/kg significantly inhibited the development of edema in a foot pad thickness
experiment, exhibiting similar results to ibuprofen (Hipol, Cariaga and Hipol, 2012).
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Borapetoside C

Borapetoside F (AP-3-293TC)

Syringin (AP-2-47-5Tc)

Tinosineside A (AP-1-42-4
Ts)

Borapetoside B (AP-2-602Tc)

Tinocordifolioside (AP-1-398 Ts)

Figure 3: Chemical structures of various constituents of T. crispa tested for cytoxicity in MCF-7
and MDA-MB-231 BC cells
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Although numerous compounds have been reported from T.crispa, few have been
evaluated for cytotoxic activity and the active compounds responsible for cytotoxicity in cancer
cells still need to be identified. Iqbal et al. reported IC50 > than 10µM for borapetoside A, B, C and
D in PC-3 cancer cells (human prostate) and normal 3T3 (mouse fibroblast) cell line (Choudhary
et al., 2010). Mantaj et al. reported selective inhibition of the expression of STAT3 and STAT3
target genes cyclin D1, fascin and bcl-2 and thus, significant toxicity against STAT3-dependent
MDA-MB 231 breast cancer cell line by crispene E, a furanoditerpenoid isolated from the hexane
fraction of T. crispa (Mantaj et al., 2015). The methanolic and other polar fractions of T. crispa
have been reported to show cytotoxic activity in different cell lines. Froemming observed a dose
dependent cytotoxic effect in methanolic extract of T.crispa on MDA-MB-231 and MCF-7 cancer
cell lines with an IC50 value of 44.8 and 33.8 µg/mL (Mantaj et al., 2011). Zulkhairi et. al. studied
cytotoxic effects of various extracts of T. crispa in different cancer cells such as breast, ovarian,
and hepatic cancer cells. The aqueous crude extract of T. crispa stem showed IC50 values of 107
µg/mL in MCF-7 cells, 165 µg/mL in HeLa cells, 100 µg/mL in Caov-3 cells, and 165 µg/mL in
HepG2 cells. They observed significant cytotoxicity of the crude aqueous extract in comparison
with cisplatin and tamoxifen, the traditionally used chemotherapeutic drugs. The major
components with anti-cancer activity still need to be investigated (Zulkhairi et al. 2008). The
evidence of anti-proliferative activity in cancer cells owing to the active chemical constituents,
such as diterpenoids and alkaloids, encouraged us to investigate the anti-cancer potential of various
T. crispa extracts uninvestigated in MCF-7, and MDA-MB-231 breast cancer cell lines. For our
project, we tested compounds (Figure 3) isolated from T. crispa by Abidah Parveen in the National
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Center for Natural Product Research. As some of these compounds have not been tested before for
in vitro cytotoxicity, we tested these compounds using cytotoxicity assays to determine the anticancer activity of various fractions in MCF-7 and MDA-MB-231 BC cell lines.

Xenotransplant models:
Mouse models are traditionally used as “gold standard” for cancer screening (Patel et al.
2014; Agorku et al. 2016; Tovar et al. 2017; Radiloff et al. 2008; Jung 2014). Advantages of using
a mouse model for xenograft study include a large number of orthotopic tissues for
xenotransplantation, availability of wide range of transgenic mice including humanized, severe
combined immunodeficient (SCID); and a higher conservation of genes, molecular pathways, and
organ systems with human beings (Veinotte et al. 2014). However, this model has several
drawbacks that limit its choice for running rapid anti-cancer drug screening assays. These
drawbacks include but are not limited to: mice are expensive; the number of pups produced per
clutch is small, a dedicated facility is required along with personnel which adds up to the costs of
housing and maintaining these animals. Moreover, tumors take longer (6-8 weeks) to develop in
mice; it is difficult to monitor tumors grown in non-transparent animals, substantial amounts of
test compounds are required for administering in mice, and the number of cells required to
xenotransplant is in the range of ~106/animal. Lastly, the number of animals used per experiment
is limited to a small number due to these reasons. There is a need to explore other animal models
to overcome the shortcomings of the mouse model that offer rapid, reproducible, and robust
outcomes as an alternative xenotransplantation studies.
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Transgenic zebrafish as an anti-cancer drug screening model:
For our project, using transgenic Casper/fli zebrafish as an alternative to the conventional
mouse model for treating breast cancer, we expect to develop an efficient model to screen the vast
array of natural compounds available at the University of Mississippi Natural Products Center.
This screen would enable us to contribute to the discovery of efficacious and safe compounds with
anti-cancer properties. The ultimate goal of this project is to find and establish the potential of new
therapeutic compounds for breast cancer that are safe and effective to augment the disease.
Zebrafish have become an attractive and widely used animal model for various diseases
including gastrointestinal disorders such as inflammatory bowel disease (Fleming et al. 2010),
alcoholic liver disease (Lin et al., 2015); brain disorders such as depression (Fonseka et al., 2016),
and neurodevelopmental disorders such as autism spectrum disorder (Meshalkina et al., 2018);
muscular dystrophies (Li et al., 2017), cardiomyopathy (Gu et al., 2017), infectious diseases as
described in a book section by Sullivan et al. (Sullivan et al., 2017); and continues to be explored
as a model organism in a whole host of other diseases.
Zebrafish have 70% similarity with human genes that encode proteins, which make
zebrafish an excellent model to study human diseases related to gene dysfunction (Howe et al.,
2013). This points to high conservation of molecular mechanisms involved in normal and disease
conditions, and compounds targeting these molecular mechanisms can be closely translated to the
context of human physio-pathogenesis (Okuda et al., 2016). Comparison of zebrafish and human
genomes reveal stark conservation in sequence and function of proto-oncogenes, angiogenic
factors, tumor suppressor, cell cycle, and extracellular matrix proteins (Zon et al., 2013). In
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addition to the genetic similarities, zebrafish offer practical and logistical advantages as an animal
model. These include high fecundity, rapid ex-vivo development of the embryos, small size, and
transparency of the embryo-larval zebrafish.
Existing zebrafish models have demonstrated human cancer cells, including breast cancer,
can grow, divide, metastasize, and induce angiogenesis similarly to rodent xenograft models
(Marques et al., 2009). Moreover, the fish can be easily handled, maintained in small volumes of
water, transferred into multiwell plates, and pose as a noninvasive cancer model to study the
exposure-dependent effects on cancer progression using high resolution microscopy (Parng et al.,
2002; Wehmas et al., 2016). Zebrafish embryos lack an active, fully functional adaptive immune
system until ~28 days which allows implantation of human cells without rejection (Lam et al.,
2004). Easy handling, low costs, and rapidness are unparalleled by other vertebrate organisms and
make it a promising system in primary tumors (Marques et al., 2009). Cancer cells interact with
their microenvironment and the whole organism to form cancers. Therefore, the cancer models
established in vitro must have in vivo complements in order to gain insights in the molecular
mechanisms as well as elucidating multicellular interactions involved with tumor progression
(Vittori et al., 2015). Xenografts of various human tumors in zebrafish have been studied over the
past decade. These xenograft models include tumors of ovaries, lung, breast, prostate, skin,
leukemia, melanoma.
For optimal visualization of red fluorescence labeled cancer cells we used a cross between
Tg(fli1a:EGFP), a transgenic zebrafish line that exhibits a green fluorescent vasculature by
expressing EGFP under fli1 promoter (Lawson and Weinstein, 2002; Stoletov et al., 2007), and
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optically transparent Casper zebrafish embryos, developed by White et al. in 2008 (White et al.,
2008a). The crossing procedure is described in the methods section.

Patient derived xenografts
More recently, zebrafish have been employed to xenograft tumor cells derived from
patients to test combination therapies against resistant tumor types which are difficult to treat with
a single conventional therapeutic. Patient derived xenografts (PDX) offer an advantage over
traditional models of pre-clinical development of oncologic drugs and provide the advantage of
evaluating the drug sensitivity in patients (Cassidy et al. 2015). Figure 4 is an illustration of the
processes involved in developing drugs from bench to bedside. PDX in zebrafish have been
successfully performed by different groups in clinical settings. PDX also offers the opportunity to
explore molecular events involved in tumor angiogenesis and metastasis, and eventually
personalized treatment (Gaudenzi et al., 2017). So far, researchers have only been able to establish
PDX in zebrafish successfully and the dosing is the next step. Neuroendocrine, breast, leukemia
and other cancers have been successfully xenotransplanted in the zebrafish embryos. These assays
are fast (3-7 days) and would provide substantial information for a clinician and aid in the
determination of tailored therapy for the patient (Deveau et al. 2017). Recently, Karkampouna et
al. xenografted human hepatocellular carcinoma cells (HCC) in zebrafish, mice, and ex vivo to
determine the expression of CRIPTO, a cell surface protein belonging to TGF-β family that is
highly expressed in various human cancers, and performed drug response assays in them
(Karkampouxna et al. 2018). The HepG2 cells expressing CRIPTO were xenografted in zebrafish
to determine the potential of the cells to migrate and develop tumor foci; combination therapy
using doxorubicin and sorafenib, standard drugs for HCC treatment, was tested targeting CRIPTO
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in ex vivo tumor cultures. Similar xenograft experiments using zebrafish are being widely
performed in clinical settings to determine new molecular targets as well as to determine best
dosing regimen specifically for the patient.

Figure 4: From bench to bedside, overview of the process of patient derived xenograft drug
discovery model.

Advantages of using zebrafish vs. mouse for xenotransplantation:
Zebrafish provide an alternative platform for a cancer model that can be traditionally
accomplished in mouse models (Yen et al., 2014). The comparison between zebrafish and mice as
xenograft models is summarized in Table 1. Additionally, morpholino injections in zebrafish
embryos can be utilized to induce a transient block in the translation of gene function and gene
inactivation, and this technique is fast and easy as compared to generating knock-out mice. Using
morpholinos, the role of genes involved in angiogenesis can be studied in targeted drug discovery
of novel therapeutic agents (Tobia et al., 2013). Evaluation of metastasis formation in currently
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used mouse models take several weeks as compared to zebrafish, where metastasis is observed as
early as one day post injection (dpi). The zebrafish tumor xenograft model therefore is sensitive
and allows observation of single cells and their daughter cells in vivo (Marques et al., 2009).
Moreover, the physiological responses to pharmacologically active compounds in zebrafish
embryo are comparable to mammalian systems (Zon and Peterson, 2005). Zebrafish embryos
provide an environment that mimics the human body, including hormones and nutrition. Also, as
compared to the conventional mouse animal model that requires a dedicated animal facility,
develops tumor slowly, in our proposed model it is feasible, less tedious and inexpensive to
xenotransplant 12-30 embryos/treatment group with cancer cells and to study the tumor growth
and progression in each treatment group. The availability of various tissue-specific fluorescent
reporter transgenic lines along with transparency of zebrafish has enabled high resolution in vivo
analysis of tumor cell progression. It also enables us to observe the interactions between host tumor
microenvironment and the tumor cells (Feitsma and Cuppen, 2008; Binder and Zon, 2013).
Even with numerous advantages rendering zebrafish as an excellent model for
xenotransplantation, there are limitations of using this model. For example, the lack of an adaptive
immune system in zebrafish embryos limits the investigation of the role of the immune system in
cancer pathogenesis and drug response (Deveau et al. 2017). Zebrafish provide a platform to
xenograft tumor cells orthotopically, the organs that are not present in fish such as breasts, lungs,
joints, limbs, and prostate glands. It is also important to note that the drugs that can be tested in
zebrafish larvae are limited by their characteristics such as molecular weight, solubility, stability
and bioavailability since the exposures are waterborne (Brown et al., 2017).
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Table 1: Mice vs. Zebrafish as xenotransplant models.

Duration of experiment

2-4 months

3-6 days

Cost

$45-60

$1-2

Maintenance costs

$1-3/mouse

Cents/tank

Number of cells required for
xenografting

~106/mouse

100-200/larva

Cancer cell tracking

Tumor mass

Single cells

Visualization frequency

End point of experiment

Everyday

Histology

Individual organs

Whole fish

Specific Aims
The goal of this project was to develop transgenic zebrafish as an in vivo animal model to
screen anti-cancer compounds for treatment of human breast cancer. The zebrafish larvae
developed for this study is a fourth-generation cross between Casper and fli strains (CF4),
possesses a transparent body with fluorescence tagged vasculature. The transparent body allows
for visualization of BC cells (labeled with red fluorescent dye) which can be traced, and the effects
of anti-cancer compounds on the tumor cells can also be observed. Our central hypothesis was to
establish the value of our transgenic Casper/fli zebrafish, using DOX, PTX, 4-hydroxytamoxifen
(4-OH-TAM), known chemotherapeutic agents used widely as a first line therapy in estrogen28

dependent/independent breast cancer subtypes. For this, anti-cancer efficacy and potential
therapeutic index for test compounds in breast cancer cell lines was first established (Aim 1),
subsequently, we described the maximally tolerated concentration of anti-cancer compounds in
vivo using zebrafish larvae (Aim 2), and in our final aim 3, we determined the efficacy and
therapeutic index of the compounds in zebrafish larvae xenografted with human breast cancer cells
(Aim 3).
Our experimental approach was accomplished in three aims utilizing in vitro assays and in
vivo assays. Briefly, three types of BC cells lines were used- Estrogen Receptor positive (ER+,
MCF-7), human epidermal growth factor 2 protein positive (HER2+, BT-474), and triple negative
(TNBC, MD-MBA-231) for the evaluation of safety and selectivity of compounds. The in vitro
assays were followed by in vivo assays to determine the maximally tolerated concentration of the
extracts and fractions, and the toxic effects, if any, associated with these compounds. The larvae
were exposed to a range of concentration of different compounds and the maximally tolerated
concentration was determined over a period of 96 hours. The concentration range determined was
subsequently administered to xenotransplanted zebrafish larvae to determine the anti-cancer
potential in an in vivo setting.
The focus of our work was to establish the transgenic zebrafish as a xenograft model using
traditionally used chemotherapeutic compounds and then with compounds that have not been tested
in zebrafish xenografts before. The establishment of this model will offer an opportunity for us to
screen more novel compounds in zebrafish larvae. We will conduct the following three specific
aims to establish the transgenic zebrafish xenograft model.
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Specific Aim 1- Establish anti-cancer efficacy and potential therapeutic
index for test compounds in breast cancer cell lines:
Hypothesis: The effect of the compounds tested (DOX, PTX, Curcumin, T. crispa, and 4OH-TAM) on the viability in cell lines (MCF-7, BT-474, and MDA-MB 231 unlabeled and labeled
with CM-DiI) will be comparable, and the CM-DiI labeled cells do not have sensitivity to the
compounds related to the dye.
Approach: Test effect of cytotoxic compounds in MCF-7, BT-474, and MDA-MB 231 cells
labeled with CM-DiI and evaluate if CM-DiI affects the cellular response to chemotherapeutic
agents and establish that the agents work as expected. For the latter outcome, 4-OH-TAM should
demonstrate a measure of inhibited cell growth in ER+ MCF-7 cells and DOX and PTX should
inhibit the growth of all cell lines.

Specific Aim 2- Demonstrate the maximally tolerated concentration
(MTC) of anti-cancer compounds in vivo using zebrafish:
Hypothesis: Maximally tolerated concentration (MTC) of chemotherapeutic drugs in the
zebrafish is comparable to the dose equivalent administered in humans.
Approach: Expose 3-day post fertilization (3 dpf) larvae to a range of concentrations of
known cytotoxic and test compounds to determine maximally tolerated concentration (MTC) that
causes minimal toxicity evaluated as phenotypic developmental defects in the zebrafish. Freshly
made doses administered every 24 hours and the phenotypic defects observed over a period of 96
hours. This proposal was approved by IACUC, protocol number- 16-007.
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Specific Aim 3: Determine the efficacy and therapeutic index of the
compounds in zebrafish embryos xenografted with human breast cancer cells.
Hypothesis: BC tumor burden will be reduced by exposing the zebrafish to the anti-cancer
compounds DOX, PTX, and 4-OH-TAM and novel test compounds screened in Specific Aim 1.
Approach: Inject the CM-DiI labeled BC cells in zebrafish embryos and exposed them to
the safe dose-range of compounds determined in Specific Aim 2 to determine the anti-cancer
efficacy of each compound by counting and comparing the number of cells in each larva using
fluorescence microscopy at 1 day post injection and at 5 days post injection. The layout for this
experiment and the timepoints are illustrated in Figure 5.

Figure 5: Layout of the xenograft experiments. Larvae will be injected with fluorescently
labeled BC cells at 2 days post fertilization, imaged at 1 day post injection (dpi), and treatment
will begin at 1 dpi. The treatment continued for 96 hours and on 5 dpi, the larvae were imaged
again to determine the change in number of cancer cells
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CHAPTER II
EXPERIMENTAL METHODS
2.1 Cell Culture
Cells were cultured and maintained according to the instructions by ATCC (Manassas,
VA). MCF-7 (ATCC® HTB-22™, provided by Dr. Tracy Brooks), MDA-MB 231 (MDA-MB231 (ATCC® HTB-26™, provided by Dr. Shabana Khan), and BT-474 (ATCC® HTB-20™,
ATCC) cells (Figure 6) were maintained in DMEM media (Life Technologies, CA) supplemented
with 10% fetal bovine serum (FBS) (Life Technologies, CA) and 1% penicillin/streptomycin
antibiotics (Sigma-Aldrich, MO) at 37 °C in humid conditions with 5% CO2. Cells were
maintained in exponential growth phase until needed for experimental procedures.

Figure 6: Breast cancer cell lines used in the in vitro and in vivo experiments. MCF-7 (A),
MDA-MB-231 (B), and BT-474 (C) were maintained in DMEM media, imaged at 10x
magnification

32

Labeling human breast cancer cells with fluorescent dye
Chloromethyl-benzamidodialkylcarbicyanine dye (CM-DiI) (Thermofisher Scientific,
CA) is a lipophilic dye that intercalates the plasma membrane of a cell and is reported to be
expressed by daughter cells for several generations. MCF-7, BT-474, and MDA-MB 231 were
labeled with CM-DiI according to the manufacturer’s instructions. Briefly, CM-DiI was dissolved
in DMSO (final concentration: CM-DiI: 4.8 µg/ml, DMSO: 0.4%). Cells were incubated with CMDiI cell-labeling solution directly diluted into phosphate-buffered saline (PBS) (2 µL of labeling
solution per mL of medium) for 4 min at 37 °C, followed by 15 min at 4 °C. The cells were then
centrifuged at 4000 rpm (2670 x g) for 3 minutes to remove unincorporated dye and rinsed twice
with PBS.

Compounds
The compounds used were doxorubicin and tamoxifen (provided by Dr. Tracy Brooks), 4hydroxytamoxifen (Sigma Aldrich), mertansine (CAS no 139504-50-0, Abovchem), ansamitocin
P-3 (CAS no. 66547-09-9, Carbosynth), monomethyl auristatin E (CAS no 474645-27-7,
Advanced ChemBlocks Inc), and curcumin (provided by Dr. Shabana Khan), paclitaxel (Sigma
Aldrich). Stock solutions of 10 mM were made using DMSO for doxorubicin and curcumin,
ethanol for 4-hydroxytamoxifen, and tamoxifen, and 1 mM stocks were made for mertansine,
ansamitocin P-3, MMAE and paclitaxel. The stocks were stored in aliquots at -20 ºC.

Cell Viability Assay
The MTS [(3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium] assay was used to determine the cell viability using colorimetric analysis. The
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basis of this assay is that tetrazolium is reduced by the NAD(P)H dehydrogenase enzyme in viable
cells. A colored formazan dye is formed upon reduction which can be detected from its absorbance
between 490-500 nm (Mosmann, 1983). Breast cancer cells were trypsinized from flasks,
centrifuged at 4000 rpm (2670 x g) for 5 minutes and resuspended in DMEM. After counting the
cells, they were diluted with trypan blue in a ratio of 1:10. Trypan blue aids in determining the
number of dead cells as it is not absorbed by viable cells. The cells were then seeded at a density
of 5.0 x 103 cells per well in a 96 well plate.
Cells were allowed to attach overnight, and test compounds were diluted over a 5-6 log
range from a high dose of 100 µM in case of traditional chemotherapeutic drugs; and 100 nM in
case of potent microtubule inhibitors, added to the cell plate and allowed to incubate for 24, 72, or
96 hours. At the end of the time point, 20 µL of a solution of 2 mg/mL MTS and 5% PMS
(phenazine methosulfate) (Promega, CA) was added to each well. The plate was incubated at 37
°C for 2-4 hours, and absorbance read on a Bio-Tek spectrophotometer (Bio-Tek Instruments, VT)
at 490 nm. Absorbance was converted into percent cell viability by first subtracting the absorbance
of the compounds and then normalizing to control cell growth. All experiments had internal
biological triplicates. GraphPad Prism 5.0 was used to determine the IC50 of each compound by
non-linear regression with curve fit using dose response-inhibition equation (log[inhibitor] vs.
response]) with variable slope. For statistical analysis, two-tailed, unpaired t-test with Welch’s
correction (not assuming equal variances) was used at 95% confidence interval. Anti-cancer
efficacy was evaluated by the IC50 in unlabeled and CM-DiI labeled MCF-7, BT-474, and MDAMB- 231 cells, and for test compounds in the cell lines.
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2.2 Zebrafish culture
The transgenic Tg(fli1a:EGFP)y1 zebrafish was generously gifted by Dr. Robert Tanguay
(Oregon State University) and roya9; mitfaw2 Casper zebrafish was purchased from Zebrafish
International Resource Center (ZIRC), catalog ID: 1689. Zebrafish were raised according to
IACUC protocol #14-020 and housed in clean, restricted access facility in Aquatic Habitats Flowthrough System (Aquatic Habitats, Florida). The light cycle for zebrafish was set to 14: 10 hours
light: dark (dark 22:00 -08:00) to simulate natural breeding conditions.
The parameters for zebrafish water were set between a range of 26-30°C for temperature;
pH 7.4-8; conductivity was adjusted using Instant Ocean salt at 60 ppm. The adult zebrafish were
fed twice daily with Gemma 300 micro food. Larvae at age 5 dpf were fed Gemma 75 micro twice
daily, and larvae at 30 dpf were fed Gemma 175 micro twice daily. For collecting eggs, mature
zebrafish were spawned once a week in a spawning trap tank in the ratio of 1:1 male to female.
Approximately two hours after the onset of the light cycle, the eggs were collected from the
spawning tank. The eggs were washed, dead and unfertilized eggs removed, and added into a
petridish containing zebrafish embryo water (sterilized deionized water, pH 7.4-7.7, 60 ppm
Instant Ocean). The eggs were incubated at a temperature of 28°C and the light cycle was set to
14:10. Subsequently, the dead embryos were removed, and embryo water was replaced as required
until the larvae were 5 dpf, at which point they were transferred in a regular tank in the zebrafish
system. For xenotransplant experiments, the eggs collected from F3 crosses were incubated at
34°C.
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Crossbreeding zebrafish
The Tg(fli1a:EGFP) transgenic zebrafish expresses the enhanced green fluorescent protein
throughout their life owing to the fli1a promoter in their endothelial cells. Casper transgenic
zebrafish, on the other hand, possess roya9; mitfaw2 genes in their homozygous recessive allelic
form. The roya9 gene imparts transparency while the mitfaw2 gene makes them devoid of pigment
(White et al., 2008b). For optimal imaging of the fluorescently labeled cancer cells in the fish, it
was imperative that the fish were transparent, lacked pigment, and had the EGFP labeled
vasculature. This ensured no interference of the inherent pigment of the zebrafish larvae in
capturing images of the CM-DiI labeled BC cells in the xenografted fish. The Tg(fli1a:EGFP) and
Casper transgenic lines were maintained and bred independently, and subsequently spawned
together to obtain the hybrid transgenic embryos. The hybrid lines were maintained and bred to
stock for experiments. The crossing technique was optimized by Dr. Faisal Albaqami. We repeated
his methods and obtained Casper X Tg(fli1a:EGFP) crosses. Briefly, adult Tg(fli1a:EGFP) males
and Casper females were spawned in a ratio of 1:1 in the breeding tanks. The eggs were collected,
washed, and dead ones were removed. Eggs were maintained in a petridish containing zebrafish
embryo water. These embryos were representative of the first generation (F1) crosses. The F1
crosses possessed heterozygous dominant wildtype and recessive mutated forms of roya9; mitfaw2
genes as a result of equal distribution of parent alleles. As a result, the F1 zebrafish expressed the
EGFP under the fli1a promoter and appeared similar to Tg(fli1a:EGFP) and all embryos express
green fluorescence in their vasculature. All the embryos were screened at 1 dpf for fluorescence
and the strong EGFP expressing embryos were selected to be raised. These embryos, upon
maturation, were spawned among themselves similarly, in the ratio of 1 male to 1 female and the
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eggs were collected. The eggs collected from the F1 spawning were the F2 generation. F2 crosses
expressing the EGFP were selected at 2 dpf and raised. The F2 crosses possessed EGFP, but there
were different phenotypes owing to inheritance patterns as shown in Figure 7. The F2 transgenic
embryos were raised, and upon reaching adulthood, bred to obtain the third generation (F3), and
the procedure was repeated to obtain F4 offspring. All zebrafish experiments for this research were
done using F4 offspring that possessed recessive mutated forms of roya9; mitfaw2 genes and
expressed EGFP under flia promoter.

Figure 7: Schematic representation of Casper and Tg(fli1a: EGFP) crosses as described in Dr.
Faisal Albaqami’s dissertation (2016).
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2.3 Maximally tolerated concentration (MTC) and no observed adverse effect
level (NOAEL) in zebrafish larvae
Maximally tolerated concentration (MTC) is the highest concentration at which the
survival of the zebrafish larvae at the end of a 96-hour exposure was more than 80%, and no
observed adverse effect level (NOAEL) is the concentration of compound at which deformities
(curved body axis, yolk sac, and pericardial edema) were not observed in larvae exposed for a
period of 96 hours. Zebrafish larvae aged 3 days post fertilization (dpf) were exposed to different
concentrations of the test compounds for 96 hours to determine MTC in the exposed larvae. Each
treatment group comprised of 12 larvae and corresponding controls treated with embryo water.
Every 24 hours, the larvae were observed under a microscope to determine survival and for any
visible phenotypic defects. Ultimately based on MTC and NOAEL, an optimal concentration of
each compound that did not cause any overt developmental defects or toxicity in the fish was
determined.

2.4 Xenotransplantation
Preparing cells for transplantation
Cells (MCF-7, BT-474, and MDA-MB-231) were prepared for transplantation using
labeling procedure as described in 2.1. The pellet was resuspended in 300 µL serum free DMEM.
The labeled cells (100-200) were injected in zebrafish embryos within 2 hours to avoid clumping
of cells.
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Preparation of zebrafish for microinjection
The F3 adult zebrafish were spawned two days before the microinjection. Eggs were
collected the next morning, dead ones removed, and incubated at 34ºC. At 1 dpf, the eggs were
examined for fluorescence and the embryos expressing EGFP were selected. At 2 dpf, the embryos
were anaesthetized using 0.02% tricaine methanesulfonate and oriented them in the dorsal position
in a petridish coated with agarose gel. The borosilicate capillaries were pulled using Sutter
Instrument P-20 ( pull = 20, velocity = 50, time = 200, pressure =200, and heat = ramp +21°C) as
suggested by Wehmas et al (Wehmas et al., 2016).

Xenotransplant of CM-DiI labeled MCF-7, BT-474, and MDA-MB-231
cells in zebrafish larvae/embryos
Xenotransplantation of the breast cancer cells in 2 dpf zebrafish embryos using a protocol
similar to the procedure described previously (Haldi et al., 2006). The number of labeled cancer
cells/mL were approximately 1x106. This pellet was resuspended in 300 µl of serum-free DMEM
and 4-5 µl of this suspension was added to a pulled needle using Eppendorf capillary tips. Five µl
of the labeled cell suspension was added to each needle. The needle was then inserted in the orifice
of the micromanipulator and trimmed using forceps. The tip of the pulled needle was then trimmed
using forceps to allow a droplet of approximately 5 nL to be injected into each fish. The number
of cells in each droplet was counted and the diameter of the droplet measured to determine the
number of cells/injection. The optimization procedure is described in Appendix I. The total number
of cells/injection were calculated to be about 100-200 in a droplet with a radius of 160 µm.
Borosilicate needles were used to microinject CM-DiI labeled MCF-7, BT-474, and MDA-MB39

231 cells in the yolk sac of 2 dpf zebrafish embryos. The microneedle was positioned at a 45degree angle to inject approximately 50 nL of the cell suspension into the yolk-sac of the larvae;
100-200 cells per larva were injected, approximately n = 60 larvae were injected for each
experiment.

2.5 Quantification of breast cancer cell proliferation
Preparation and mounting of xenotransplanted zebrafish for
fluorescence microscopy
At 1 dpi, the xenotransplanted zebrafish larvae were anaesthetized in a 0.02% tricaine
solution and then mounted in 110 µL of 0.8% low melt agarose in tricaine in 48 well plates. The
agarose gel was allowed to cool down before adding anaesthetized larvae in each well. The larvae
were positioned using a pipette tip in a lateral position to image the yolk sac. The imaging was
done at 1 dpi to identify the fish with cancer cells and remove the ones that did not have cancer
cells or were deformed. After imaging the larvae and selecting the ones with the tumor cells at 1
dpi, the larvae were exposed to different concentrations of each compound with 20-30
larvae/treatment (approximately 30 larvae were injected for each treatment group, but at 1 dpi
some of them died, had edemas, or did not have cancer cells and were eliminated from further
evaluation) in 48 well plates. The larvae were exposed to the compounds at concentrations
determined from the in vitro IC50 values and the in vivo MTC and NOAEL assays in water for 96
hours in 48 well plates. The effect of these compounds on the malignant cells was then observed
as the distance traveled by the cancer cells from the site of injection after treatment with the
compounds. In Trial 1, MCF-7, BT-474, and MDA-MB-231 xenografted larvae were treated with
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10 nM mertansine (n = 12) for comparison of metastatic behavior in three cell lines. Subsequently,
in Trial 2, MCF-7 xenografts were treated with 10 nM mertansine and 25 nM PTX in three
independent experiments (n = 6-19). In Trial 3, MCF-7 xenografts were then treated with 200 nM
mertansine in three independent experiments, and MDA-MB-231 xenografts were treated with 200
nM mertansine and 25 nM PXT in two independent experiments. The xenografted fish were
exposed to the selected concentration of compounds for 96 hours starting at 1 dpi, observed every
24 hours for morphological changes and mortality, and the dose refreshed. After the 96-hour
dosing period, living larvae were imaged similarly at 5 dpi to determine the proliferation and
metastasis of cancer cells and the effect of treatment on the number of cancer cells.

Imaging the xenotransplanted zebrafish larvae
The xenotransplanted larvae were imaged using Nikon Eclipse Ti2 microscope using
triggered tetramethylrhodamine isothiocyanate (TRITC) (excitation wavelength 550 nm and
emission wavelength 580 nm) and fluorescein isothiocyanate (FITC) (excitation wavelength 494
nm and emission wavelength 518 nm) acquisition, where both TRITC and FITC wavelengths were
emitted simultaneously. The exposure times used for TRITC and FITC filters were 200
miliseconds with 100% and 50%, intensities respectively. We obtained z-stacks of the fish using
triggered FITC and TRITC settings and 10x + 1.5x objective was used. Each z-stack was 15 µm
thick. The images were acquired using NIS Elements software (Nikon).

Analysis of images obtained
The fluorescent images were analyzed by selection of every second z-stack slice. The
TRITC look up table (LUT) was adjusted to eliminate background and autofluorescence, and was
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kept at the same LUTs for the entire fish. The site of injection was determined, and graticules
(concentric circles starting at the site of injection then moving out, 100 microns apart) were
centered on the site of injection. Each circle moving out from the site of injection was 100 µm
away along the entire length of the fish as shown in Figure 8. Next, cells were manually counted
using only the TRITC filter image. The number of cells were counted from each selected z-frame
and in every 100 µm ring. The percent incidence of the number of cells that traveled beyond
distances of 500, 1000, 1500, 2000, and 2500 nm from the site of injection were calculated. Data
was analyzed using GraphPad Prism 5.0 and Two-way ANOVA was performed to determine
statistical significance using Sidak’s multiple comparisons.
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Figure 8 Pictomicrograph showing xenografted larva at 5 dpi (A) and in (B) the cell counting
procedure using graticules in blue, each at a distance of 100 microns away from the site the
injection. The green plus sign indicates each individual breast cancer cell. Number of cells in
each graticule were manually counted.
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CHAPTER III
ZEBRAFISH AS AN IN VIVO SCREEN FOR COMPOUNDS WITH ANTICANCER ACTIVITY IN HUMAN BREAST CANCER
3.1 Results
Determination of in vitro cytotoxicity in labeled vs unlabeled breast
cancer cell lines
To determine if the breast cancer cell lines that were labeled with CM-DiI possessed
different sensitivity to standard chemotherapeutic compounds as compared to the unlabeled cells,
MCF-7 and MB-231 cells were plated and treated with a log dose range for 72 hours. Figure 9
shows the treatment of MCF-7 cells with DOX and 4-OH-TAM. The IC50s of doxorubicin and 4OH-TAM in labeled and unlabeled cells were 0.33 ± 0.41 µM and 0.47 ± 0.038 µM, and 27.48 ±
0.52 µM and 28.80 ± 0.71 µM, respectively. A significant difference in the IC50s of labeled vs
parental cell lines was neither observed, for 4-OH-TAM (n = 3, p = 0.0578, two-tailed unpaired ttest) nor for DOX (n = 3, p = 0.2288, two-tailed unpaired t-test)
Tinospora crispa extracts (Table 3) were tested in both labeled and unlabeled MCF-7 and
MDA-MB-231 cells at concentrations ranging up to 100 mg/mL (Figure 10). Only data from the
unlabeled experiments is shown. No cytotoxic effects were observed at any concentration of the
ten extracts.
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Next, the potent microtubule inhibitors, mertansine, ansamitocin P-3, and MMAE were
tested in vitro in MCF-7, BT-474, and MDA-MB-231 labeled and unlabeled cells (results shown
in Appendix I) in multiple batches and repetitions to encompass a wide range of concentrations.
Initially, it was challenging to get a stable solution of PTX, and it required multiple attempts and
repetitions to achieve a stable solution where PTX did not precipitate out of solution. The ultimate
concentration of PTX that was stable in DMSO was 1 mM and the freshly prepared stock was
stored at -20°C in aliquots. Mertansine and PTX IC50 values in MCF-7 cells were 0.120 ± 0.02 µM
and 0.39 ± 0.06 µM, respectively. For MDA-MB-231 cells, the IC50 values for mertansine and
PTX were 0.09 ± 0.02 µM and 0.26 ± 0.04 µM, respectively. In BT-474, the IC50s were 0.11 ± 0.03
µM and 0.57 ± 0.1 µM, respectively (Figure 11). Mertansine was most cytotoxic in MDA-MB231 cells with an IC50 value of 0.09 µM whereas PTX was most toxic in MCF-7 cells.
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Figure 9: Determination of potential sensitivity to CM-DiI in MCF-7 labeled and unlabeled cells
after treatment with 4-OH-TAM and doxorubicin. The cells, in triplicate wells, were exposed to
drugs for a period of 72 hours. No statistically significant difference was found in the IC50’s of
labeled vs unlabeled cells in response to the treatment tested using a two-tailed unpaired t-test with
Welch’s correction without assuming equal variance at 95% confidence
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Table 2: Tinospora crispa fractions tested in MCF-7 and MDA-MB-231 cells for cytotoxicity
Compound 1

AP-3-39-3TC

Compound 2

T. Crispa methanolic extract

Compound 3

Tinosineside A (AP-1-42-4 Ts)

Compound 4

AP-TC-But

Compound 5

T. Crispa ethyl acetate fraction

Compound 6

T. Crispa chloroform fraction

Compound 7

Borapetoside E (AP-3-29-3Tc)

Compound 8

Borapetoside B (AP-2-60-2Tc)

Compound 9

Borapetoside F

Compound 12

Syringin (AP-2-47-5Tc)
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Figure 10: Determination of cytotoxicity of Tinospora crispa fractions in MDA-MB-231 and
MCF-7 cells. The cells, in triplicate wells, were exposed to Tinospora crispa fractions (see Table
3 for fractions corresponding to legend numbers) for a period of 72 hours. No toxicity was
observed in either cell line upon treatment with these compounds for a period of 72 hours.
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Figure 11: Determination of cytotoxicity of mertansine and paclitaxel in A) MCF-7, B) BT-474,
and C) MDA-MB-231 cells. The cells, in triplicate wells, were exposed to different concentrations
of mertansine and paclitaxel for a period of 24 hours
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Determination of NOAEL and MTC of test compounds in zebrafish:

Figure 12: Survival of zebrafish larvae after an exposure to different concentrations of
doxorubicin, pravastatin, curcumin, and 4-OH-TAM (n=12) to determine the maximally tolerated
concentration in the larvae. The exposure started at 3 days post fertilization (dpf), doses were
renewed every 24 hours up to 96 hours and the deformities were also noted.
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Three-day old zebrafish larvae were plated in 48 well plates, one fish per well, and were
dosed with varying concentrations of compounds for a period of 96 hours. The test chemical was
re-administered every 24 hours and the larvae were observed for any deformities. The percent
incidence of deformities observed at MTC in mertansine, ansamitocin P-3, MMAE and PTX are
listed in Table 4. The MTC and the NOAEL were determined after the end of the exposure and a
concentration lower than MTC was used as treatment for the xenotransplanted larvae. Observed
MTCs for doxorubicin, 4-OH-TAM, PTX, curcumin, pravastatin, mertansine, ansamitocin P-3,
and MMAE are listed in Table 3 below. For MMAE, 83% and 91% of the larvae survived at
concentrations of 700 and 800 nM, but higher incidences of deformities were noted at these
concentrations. For mertansine and PTX, the MTC was determined from three independent
experiments (Figure 14), and we selected 25 nM for PTX, and 10 and 200 nM mertansine as the
therapeutic concentration in our xenograft experiments.

51

Figure 13: Survival of zebrafish larvae after an exposure to different concentrations of potent
microtubule inhibitors to determine the maximally tolerated concentration in the larvae (n = 12).
The exposure started at 3 days post fertilization (dpf), doses were renewed every 24 hours up to
96 hours and the deformities were also noted.
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Figure 14: Survival of zebrafish larvae after an exposure of 10-100 nM of PTX and mertansine
(n = 12).
Table 3:.MTC and NOAEL determined for various anti-cancer compounds
Compound

MTC

NOAEL

Doxorubicin

6.5 µM

NM

Curcumin

0.5 µM

NM

Pravastatin

40 µM

NM

Paclitaxel

100 nM

25 nM

Mertansine

800 nM

400 nM

Monomethyl auristatin E

800 nM

400 nM

Ansamitocin P-3

100 nM

50 nM
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Table 4: Percent incidence of deformities observed in larvae at MTC
Percent incidence of deformity observed at MTC
Compound
Mertansine
MMAE
Ansamitocin P-3
Paclitaxel

Yolk sac/Pericardial
edema
30
50
45
40

Curved body axis
60
90
65
50

Validation of transgenic zebrafish as a xenotransplant model for human
breast cancer:
Three sets of trials (Table 6) aimed at answering questions about the validation of zebrafish
as a xenotransplant model were performed. In the first experimental group, Trial 1, the metastatic
behavior of MCF-7, BT-474, and MDA-MB-231 cells in vivo was observed at 1 and 5 dpi (Figure
15 and 16, respectively). Counting and analysis of cancer cells in the xenografts at 1 dpi showed
in only a few zebrafish larva the cancer cells traveled beyond 600 micrometers from the site of
injection (Figure 15). The larvae were then randomly distributed into control and treatment groups
(n = 12), and treated with 10 nM mertansine. As it was observed that not many cells in either of
the three experimental groups traveled beyond a distance of 500-600 micrometers from the site of
injection at 1 dpi, it would be worthwhile to assess the total number of cells in each xenograft at 5
dpi, as well as to determine the number of cells that traveled beyond the 500 µm distance mark as
this was the farthest distance traveled by the cells in any of the three xenograft experimental
groups. At 5 dpi, the total number of cells in the larvae as well as the percent incidence of cancer
cells that traveled a beyond 500 micrometers from the site of injection in each larva at 5 dpi was
determined in control and treatment groups. The effect of treatment on distance travelled by the
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cancer cells from the site of injection in larvae xenografted with the three different cell types
xenotransplanted was evaluated. Comparison of the total number of cells between the three BC
xenograft experimental groups suggests that there was no significant difference in the metastatic
potential of MCF-7, BT-474, or MDA-MB-231 cells or in the percent incidence of cells that
traveled beyond 500 µm in the three cell lines in Experiment 1(n = 12, One-way ANOVA) (Figure
17).
For MCF-7 xenografts, in 25 nM PTX treated larvae in two of three experiments in Trial
2, a 50-60% decrease (Figure 18) in the fold change of percentage of cells beyond 500 µm from
the site of injection and in fold change in total number of cells as compared with controls was
observed. This decrease was consistent with the overall significant reduction of percentage of cell
that traveled beyond 1000 µm in PTX treated group (Figure 19 (B)) (n = 6-10, One-way ANOVA,
p <0.05). For MDA-MB-231 xenografts, in 25 nM PTX treatment groups, there was a 10-20%
decrease in the fold change in percentage of cells beyond 500 µm and fold change in total number
of cells as compared to controls. A 55% decrease in the total number of cells was also observed in
the 25 nM PTX group as compared to controls. However, a significant reduction of the percent
incidence of cells beyond 500 and 1000 µm in PTX treated larvae was not observed. These data
point to effectiveness of 25 nM PTX in MCF-7 and MDA-MB-231 xenografts.
For MCF-7 xenografts treated with 10 nM mertansine, a 50-60% reduction in fold change
in percentage of cells beyond 500 µm and 20-30% decrease in fold change in total number of cells
as compared to controls was observed in three out of four experiments. Also, a significant
reduction in tumor burden beyond 500 and 1000 µm from the site of injection was observed in the
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10 nM mertansine treatment groups (Figure 19) (n= 6-13, One-way ANOVA, p<0.05. In MDAMB-231 xenografts in the 10 nM mertansine treatment group, approximately 10% reduction was
observed in the fold change in percentage of cells beyond 500 µm and fold change in total number
of cells as compared to controls. However, 10 nM mertansine was not effective in reducing tumor
burden in MDA-MB-231 xenografts as compared to controls.
For MCF-7 xenografts treated with a higher concentration of mertansine, 200 nM, it was
observed that a 20-60% decrease in the fold change in percentage of cells beyond 500 µm and 4050% decrease in fold change in total number of cells as compared to controls was observed in four
experiments. Overall, a 75% reduction in the fold change in percentage of cells beyond 500 µm
was observed in 200 nM mertansine groups. Interestingly, a significant reduction in the total
number of cells, percent incidence of cells beyond 500 µm, and 1000 µm was observed in the three
experiments with 200 nM mertansine treatments (Figure 19) (n= 4-15, One-way ANOVA,
p<0.05). In MDA-MB-231 xenografted larvae treated with 200 nM mertansine, there was a 10%
reduction in tumor burden beyond 1000 µm as compared to controls but it was not significant (n
= 22, One-way ANOVA).
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Table 5 Trial 1-Determination of metastatic behavior of MCF-7, BT-474, and MDA-MB-231
cells in zebrafish xenografts
Exp 1 (MCF-7)
Mert
Ctrl
(10 nM)
Average total
number of cells
Total number of
fish at 5 DPI/
Total number at 1
DPI

Exp 2 (MDA-MB-231)
Mert
Ctrl
(10 nM)

Exp 3 (BT-474)
Mert
Ctrl
(10 nM)

290±80

208±60

288±67

209±75

202±70

147±80

12/20

12/20

12/20

12/19

12/22

12/21
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Figure 15: Zebrafish larvae xenografted with the three BC cell lines were imaged for detection of
cancer cells at 1 dpi and randomly sorted into control and treatment groups. The images for larvae
that survived until 5 dpi in both control and treatment groups were then analyzed for the distance
traveled by cancer cells from the site of injection in each larva at 1 and 5 dpi. Distance traveled by
MCF-7 cells in A) control group and D) treatment group, BT-474 cells in B) control group and E)
treatment group, and MDA-MB-231 cells in C) control group and F) treatment group.
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Figure 16:Zebrafish larvae xenografted with the three BC cell lines were imaged at 5 dpi.
Distance traveled by MCF-7 cells in A) control group and D) treatment group, BT-474 cells in
B) control group and E) treatment group, and MDA-MB-231 cells in C) control group and E)
treatment group.
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Figure 17: Trial 1 with MCF-7, BT-474, and MDA-MB-231 cells xenografted in zebrafish larvae.
A) Total number of cells in MCF-7, BT-474, and MDA-MB-231 xenografts in the control group
at 5 dpi (n = 12). B) Percent incidence of cells beyond 500 µm from the site of injection in MCF7, BT-474, and MDA-MB-231 xenografts in the control group at 5 dpi (n = 12).
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Figure 18: Fold change in A) percentage of cells beyond 500 µm, and B) in total number of cells
in MCF-7 xenografted larvae treated with 25 nM Paclitaxel as compared with controls in each of
three experiments. N = 9-15
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Figure 19:Percent incidence of cells that traveled beyond A) 500 µm and B) 1000 µm in Trials
1, 2, and 3 in zebrafish larvae xenografted with MCF-7 cells at in Trials 1, 2, and 3 at 5 dpi. Data
analyzed using one-way ANOVA, *(p<0.05) and ***(p<0.0001) (n = 4-13).
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3.2 Discussion
We hypothesized that zebrafish larvae xenografted with human breast cancer cells and
treated with traditionally used chemotherapeutics would exhibit a decrease in the number of cancer
cells throughout the body of the zebrafish larvae as compared to the untreated controls. Three
different breast cancer cell lines which encompass the three subtypes of breast cancer- ER/PR+
(MCF-7), HER2+ (BT-474), and TNBC (MDA-MB-231) were used. The characteristics that
define these subtypes include, but are not limited to, their metastatic potential which attributes
aggressiveness to the breast cancer cells. Zebrafish xenografts of human breast cancer represent
an interplay between tumor and host cells, and the subsequent upregulation or downregulation of
molecular signals facilitate migration of the tumor cells to different organs in the host. Our model
offers the opportunity to study molecular mechanisms that are involved in the metastatic processes
and to understand the role of key players.
The fluorescence of cancer cells is vital in the screening studies as it makes visualization
and tracking of cancer cells in vivo feasible using live animals under a fluorescence microscope.
Determining if the CM-DiI dye labelling makes the cells differentially sensitive to test compounds
was important as it could affect the interpretation of the results. We did not find any significant
difference in the IC50 values when labeled and unlabeled breast cancer cells were treated with the
test compounds (Figure 9). Similarly, in order to determine if the labeled cells behaved differently
or if there were artifacts produced by the dye, Ghotra et al. (2012) transfected PC3 prostate cancer
cells with mCherry, and injected zebrafish larvae with labeled CM-DiI as well as mCherry labeled
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PC3 cells. They did not find any significant changes in the migration pattern of the tumor cells in
the two groups (Ghotra et al., 2012). Our results from the in vitro cytotoxicity studies also indicate
that CM-DiI is a reliable tool to label and observe the metastatic patterns and in determining anticancer potential of established and test compounds in vitro, and literature supports its use in vivo.
Potent microtubule inhibitors used in this study-mertansine, ansamitocin P-3, and MMAE were
tested in all three BC cell lines to determine their cytotoxicity. IC50 values for mertansine and
MMAE are not available for MCF-7, BT-474, and MDA-MB-231 cell lines in the literature. The
IC50 values for these compounds are listed in Table 7.

64

Table 6 IC50 values of microtubule inhibitors in literature

IC50 in vitro
(literature)

IC50 values
(our results)

Mertansine

MMAE

1.10 nM SK-Br-3 and
KB (Wayne C.
Widdison et al., 2006)

0.1 nM H3396 breast
carcinoma (Doronina
et al., 2006)

• 0.02 nM MCF-7
• 0.150 nM MDAMB-231 (Venghateri
et al., 2013)

•

• 0.095 ± 0.03 µM
MCF-7
• 0.07 µM MDAMB-231
• 0.049 ±0.01 µM
BT-474

• 0.120 ± 0.02 µM
MCF-7
• 0.09 ± 0.02 µM
MDA-MB-231
• 6.7 ± 2.6 µM
BT-474

•
•

0.150 ±0.02 µM
MCF-7
0.050 µM MDAMB-231
0.04 ± 0.01 µM
BT-474

Ansamitocin P-3

The NOAEL of different compounds, standard chemotherapeutics used in BC treatment,
and test compounds with potential anti-cancer activity, was determined in zebrafish larvae for a
period of 96 hours starting at 3 dpf (Table 4). The NOAEL and MTC provide a range of safe dosing
concentrations that can be used in the xenograft assays. In most published xenograft studies using
zebrafish, the xenografted larvae are dosed with a range of concentrations of known or test
compounds to determine the cytotoxic effect on the tumor cells. In our study, we first determined
the safe dosing range in un-injected larvae before treating the xenografts. This, in addition to the
in vitro IC50 values, provides us with a wide range of concentrations for exposure in the xenografts.
We used 25 nM for PTX, and 10, and 200 nM for mertansine in the xenografts as concentrations
observed as NOAEL. In mice, PTX is administered i.v./i.p. or in the tail at a concentration of 10
mg/ml in a solution of cremophor (Ma et al., 2015) whereas in humans, for treatment of metastatic
breast cancer, concentration up to 175 mg/m2 is administered over three hours every three weeks.
65

In patients who are prone to hypersensitivity reactions, dexamethasone (20 mg) is administered as
premedication to PTX (Quock et al., 2002). To our knowledge, mertansine. MMAE, and
ansamitocin P-3 have not been tested in zebrafish previously for toxicity.
Zebrafish has been extensively used as a xenograft model for different hematologic and
solid human tumors as summarized by Drabsch (Drabsch et al. 2017). The zebrafish xenograft
model presents numerous advantages such as requirement of small spaces for housing, inexpensive
cost of breeding, EGFP labeled vasculature that makes visualizing angiogenesis feasible, ease of
xenografting hundreds of animals per experiment, and live microscopy of the entire organism. Few
limitations are still to be considered when using this model system. One of the limitations include
incubation temperature, which is different for human cells (37°C) and zebrafish larvae (28°C). To
overcome the difference in temperature, an optimal temperature was determined (34°C) which
does not affect the growth of cancer cells or of the zebrafish larvae but is lower than normal human
body temperature. The lack of an immune system should be considered when performing the
xenograft assays as in a clinical setting immune cells have a key role in both facilitating as well as
in eliminating tumor cells.
The xenograft experiments were performed in three different settings to compare the effect
of PTX and low and high concentrations of mertansine. The zebrafish were injected with MCF-7,
BT-474, and MDA-MB-231 cells (n = 12) and treated with 10 nM mertansine (as determined from
the IC50 from the initial MTS assay) in Trial 1. The rationale behind Trial 1 was to determine if
the metastatic potential of the three BC cell lines was also represented in vivo. No significant
differences in the migration pattern of the three cell lines were found to suggest a difference in the
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migration pattern between these cell lines. Similar results for MCF-7 and BT-474 cells xenografts
were observed by Eguiara et al., where xenografted single cells derived from BT-474
mammoshperes, and parental cells from monolayer cultures to observe the migration pattern
between the two types. They observed higher migration potential in xenografts with
mammospheres and a weak metastatic potential of the monolayer culture cells, which is consistent
with what we observed (Eguiara et al., 2011). However, another group found the BT-474 to be
more metastatic as compared to MCF-7 cells in xenografts (Ghotra et al., 2012). This points to a
need for understanding the factors that may be involved in the migration of cells in the xenografts.
Firstly, the experimental factors such as site of injection, number of cells injected, incubation
temperature, are all to be considered for the migration of cells in the xenografts. Eguiara et al,
similar to us, injected the BT-474 in the yolk sac of the zebrafish at 2 dpf and the xenografts were
incubated at 28 as well as 34°C. The only difference was that they injected approximately 500
cells in each larva. Ghotra et al., on the other hand used the same incubation temperature of 34°C,
injection site yolk sac, and ~100 cells/larva. It is worthy to note that even with 500 cells, the
monolayer BT-474 did not show high metastatic potential ((Eguiara et al., 2011), whereas ~100
cells showed high metastatic potential under the same setting for Ghotra et al. Therefore, the
number of cells injected can be ruled out to be a factor involved in the aggressiveness of the tumor.
Other factors such as tumor microenvironment, may also be involved in the metastasis of the cells
in vivo. Even with an investigation of the various molecular factors that may be involved in tumor
cells migration in the xenografts, such as VEGF and neutrophils ((He et al., 2012), in metastasis
of tumor cells to hematopoietic tissues in melnoma xenografts as early as 30 minutes post injection,
the role of zebrafish tumor microenvironment is not well described in the literature and needs
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further investigation.
In these experiments, two different methods of analyzing the data were used to determine
reduction in tumor burden in treatment groups versus controls. In one method, data was normalized
to controls to determine the fold change in tumor cells, and in the second method, the percentage
of cells beyond 500 and 1000 µm were normalized with the total number of cells within that one
larva. The 10 and 200 nM mertansine were found to be effective in significantly reducing the tumor
burden in MCF-7 xenografts whereas the same results were not observed for MDA-MB-231
xenografts. This may be due to less sensitivity of MDA-MB-231 cells to mertansine, although a
10% reduction in tumor burden was observed in both treatment groups beyond 500 and 1000 µm
for 10 and 200 nM mertansine, respectively, this change was not significant. Moreover, an increase
in total number of cells was observed in the MDA-MB-231 xenografts treated with 200 nM
mertansine as compared to controls. Higher concentrations of mertansine need to be tested to
determine efficacy in MDA-MB-231 xenografts.
For MCF-7 xenografts treated with 25 nM PTX, a significant reduction in tumor burden
was observed in MCF-7 xenografts, when tested using different methods for analysis. This
indicates an effective positive control for MCF-7 xenografts. In MDA-MB-231 xenografts, a
reduction in tumor burden was observed in the two experiments with PTX treatment, however,
this reduction was not statistically significant as compared to controls. This may also point to less
sensitivity of MDA-MB-231 cells to PTX as observed with mertansine treatment. Treatment with
higher concentration of PTX is required to further confirm efficacy in the MDA-MB-231
xenografts.
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To the best of our knowledge, PTX has not been tested in zebrafish xenografted with breast
cancer cell lines even though it is one of the most commonly used chemotherapeutics for the
treatment of breast cancer in humans. Jung et al (2012) tested different concentrations of PTX in
zebrafish xenografted with oral carcinoma cells (YD10B and HSC-2) and two colon cancer cell
lines (HCT116 and DLD-1) to observe the effects of PTX on cancer cell dissemination and found
effectiveness at 100 nM PTX (Jung et al., 2012). In addition to PTX, other standard
chemotherapeutic drugs that have been tested for validation of the zebrafish xenograft model using
other human tumor cells include use of rapamycin, (mTOR inhibitor- inhibits lymphangiogenesis
in zebrafish and mammals) to determine inhibition of lymphangiogenesis, an important step in
tumor metastasis; as a positive control to screen compounds with potential inhibition of
lymhangiogenesis (Astin et al., 2014).
A significant decrease in both the overall number of cells as well as the distance traveled
by the MCF-7 cancer cells from the site of injection in the zebrafish xenografts treated with PTX
was observed. The treatment of the xenografts with mertansine (10 and 200 nM) demonstrated a
higher survival in the xenografts and a reduction in the total number of cells as well as a decline
in the number of cells that proliferated and traveled larger distances in the zebrafish from the site
of injection in the yolk sac to the trunk and tail regions. These results aid us in the validation of
the zebrafish xenograft model for the screening of anti-cancer compounds for human breast cancer.
The determination of concentration of the compounds for exposure in xenografts was
dependent on many factors. The original hypothesis was to use a concentration that was higher
than the IC50 values, and between the range determined from the MTC and NOAEL observations.
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However, for PTX, 25 nM (NOAEL) was used, which is lower than the IC50 for PTX. Poor
solubility of PTX in water was a major drawback for the zebrafish exposures, resulting in use of a
low concentration stock solution (4 mM) from which smaller dilutions were made and aliquots
were used to make fresh doses every day for the exposures. However, at 50 and 100 nM
concentrations, higher incidences of deformities were observed in the larvae, and NOAEL was
observed at 25 nM which is indicative of interference of PTX at concentrations higher than 50 nM
to interfere with the molecular mechanisms in zebrafish. A reduction in tumor burden in both
MCF-7 and MDA-MB-231 xenografts at 25 nM further suggests that the effect of PTX that may
be due to the effective uptake of the compound from water by the larva. PTX, due to its poor water
solubility, is administered in mice and humans in a Cremophor solution (polyethyleneglycerol
tricinoleate) and dehydrated ethanol, and is diluted in 0.9% (w/v) sodium chloride to make a final
concentration of PTX of 0.3 and 1.2 mg/ml. The pharmacokinetics of PTX are known to be nonlinear and the it is likely that Cremophor contributes to the nonlinearity. A typical injection of 2,
10, and 20 mg/kg in mice and 2 and 10 mg/kg in humans in Cremphor showed similar levels of
Cremophor in patients as compared to mice indicating the role of Cremophor in non-linear
pharmacokinetics of PTX (Willyard, 2018). It is important to note the involvement of vehicles
such as Cremophor in the pharmacokinetics of drugs while extrapolating the effective
concentrations of potent chemotherapeutic compounds administered as pharmaceutical
formulations.
Mertansine is more potent than PTX, and because of this reason it is being extensively
investigated in the development of antibody drug conjugates. The high potency of mertansine
makes it toxic and it has an insufficient therapeutic window (Helft et al., 2004). The solution is the
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development of ADC’s with the goal to achieve effective and targeted cancer cell cytotoxicity
without the substantial toxicity mertansine would upon administration as a single agent. The
monoclonal antibodies bind to the target tissue in a selective manner to reduce the intrinsic toxicity
to the host tissues and results in an accumulation of the payload in the target tumor tissue (Xie et
al., 2004). Cantuzumab mertansine (huC242-DM1) is an approved ADC with four molecules of
mertansine as the payload, humanized monoclonal antibody huC242 (specifically binds to the
extracellular domain of tumor- associated carbohydrate antigen CanAg (for cancer antigen), a
glycoform of MUC1, which is strongly expressed in many different solid tumors such as
pancreatic, colorectal, biliary, gastric, uterine, bladder, and non-small cell lung cancers
(Baeckström et al., 1991; Xie et al., 2004), and linked by disulfide bonds (Xie et al., 2004). The
zebrafish xenograft model can be utilized to study the efficacy of ADC’s with different
combinations of antibodies and linkers with potent payloads in a short-term assay, aiding in rapid
screening of ADC combinations. This represents a rapidly growing area of drug development and
approximately 12 ADC’s have been approved by FDA in the past decade alone and different ADC
combinations are currently being investigated in clinical trials for various cancers. Using a
zebrafish xenograft to screen the different components for targeted delivery in breast cancer could
provide important insights to molecular interactions and efficacy for drug development.
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CHAPTER IV
FUTURE DIRECTIONS
Our study successfully developed a xenotransplantation model for the screening of anticancer compounds. Potent microtubule inhibitors that have been studied for decades, were tested
in zebrafish larvae xenografted with human breast cancer cell lines. Mertansine, ansamitocin P-3,
and MMAE have not been tested in zebrafish for developmental toxicity or in vivo anti-cancer
treatment. With the establishment of the xenograft model, we can now study the effects of
ansamitocin P-3 and MMAE and other components of ADCs in zebrafish xenografted with MCF7, BT-474, and MDA-MB-231 cell lines to determine the response of these cell lines to these
compounds.
The other two components of the ADC- the linkers and the antibodies will be tested, first
in zebrafish larvae, and subsequently in xenografts. These studies present their own set of
challenges owing to larger molecular weight of antibodies and the compatibility of humanized and
mouse antibodies with zebrafish. This would be a unique opportunity to observe the efficacy of
various combinations of antibodies and linkers. In several cancer patients, the cancer cells develop
resistance to conventional therapies and the patient stops responding to treatment. Zebrafish
xenografts of tumors derived from patients, PDX, are excellent models in the drug discovery field
and for development of precision medicine as these assays are quick, short, and are useful in
predicting the anti-cancer efficacy of novel test compounds, and the responses to conventionally
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used chemotherapeutic drugs in case the tumors develop resistance. In clinical settings, zebrafish
PDX model offers the advantage of using a large number of larvae which helps in ruling out
variance in animals, the number of cells required are also less (~200/larva), and the amount of
compound required for the treatment is also low aiding in efficient medium throughput assays.
Zebrafish as a PDX model for multiple myeloma (Lin et al., 2016) was shown to exhibit similar
responses to standard chemotherapeutic drugs used for multiple myeloma (MM) bortezomib and
lenalidomide, and four novel compounds in dexamethasone resistant and dexamethasone sensitive
cell lines (MMIR and MMIS, respectively) and subsequently tested the response in patient derived
xenografts from two newly diagnosed and four relapse MM patients. This study validated the use
of zebrafish for PDX using primary MM cells. Zebrafish PDX for different solid and hematologic
tumors presents a research field with enormous potential for exploration and development of novel
anti-cancer compounds for fast detection of effective therapies tailored for individual patients.
In this study we were able to develop a human breast cancer zebrafish model based on the
skeleton established by the work of one of the previous graduate students, Dr. Faisal Albaqami,
and for the first time in our lab, we were able to quantify, by counting, the proliferation of breast
cancer cells in vivo.
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OPTIMIZATION

In vitro optimization
Transfection vs. Lypophilic dye
For visualization of BC cells in the xenografts, the cancer cells were fluorescently tagged.
Initially, the cells were transfected with a red fluorescent protein plasmid pCMV DsRed Express
2. Upon visualization under a fluorescence microscope, we observed that a small percentage of the
transfected cells did not exhibit fluorescence. Moreover, the MTS assays performed in transfected
cells vs parental control cells showed significant sensitivity among the two sets of cells. Therefore,
we decided to use CM-DiI to label the cells and cells showed fluorescence up to nine days after
they were labeled (Figure 1).

Figure 21: MDA-MB-231 cells labeled with CM-DiI visualized under TRITC filter.

Effect of media on growth of different cancer cells:
To determine the effect of media on the three different cell lines, BT-474 and MDA-MB231 were grown in DMEM supplemented with 10% FBS and 1% P/S 37º C for a period of one
87

week and compared the growth (number of cells) with the BT-474 growing in Hybri-Care Medium
(ATCC® 46-X™) media supplemented with 10% FBS and 1% P/S and MDA-MB-231 cells
growing in DMEM F12 supplemented with 10% FBS and 1% P/S. We did not observe any
significant changes in the number of cells growing in the two flasks. Therefore, to eliminate the
variables, we maintained MCF-7, BT-474, and MDA-MB-231 cell cultures in DMEM
supplemented with 10% FBS and 1% P/S.

Effect of Doxorubicin in zebrafish larvae
Zebrafish larvae were exposed to different concentrations of DOX (0.5-25µM) over a
period of 96 hours with replacement of doses every 24 hour and observation for deformities (Figure
12). At 6.5 µM or higher concentrations, there was an accumulation of DOX in the intestinal cavity
of the larvae starting as soon as 24 hours post treatment. The accumulation was observed to be
more in larvae exposed to higher concentrations. The larvae exposed to a concentration of 25µM
were deformed and did not survive. Moreover, we observed that larvae exposed to DOX, when
observed under a fluorescence filter (TRITC) exhibited red fluorescence as shown in Figure. This
was an indication of uptake of DOX by the larvae and provides support to our waterborne
exposures in the larvae. However, this contradicted with the fluorescence of the CM-DiI labeled
BC cells and we decided not to use DOX as our positive control.
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Figure 20 Pictomicrographs of 4-day old zebrafish larvae after exposure to 12.5 µM DOX for 24
hours. Image acquired at 10x magnification using brightfield, FITC, and TRITC filters
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In vivo optimization
Preparation of agar coated petridish for microinjection:
For injecting zebrafish larvae at 2 and 3 dpf the larvae were placed in a plastic petridish
positioned dorsally against a glass slide. The larvae were unstable and low survival rate after
injection was observed. The larvae require an appropriate setup to survive the microinjection and
at the same time, be stably positioned so the microinjection procedure can be efficiently carried
out. Therefore, we used low-melting agarose gel (0.1%) to coat the petridish and before the gel
solidified completely, we used capillaries to make indentations in the gel for positioning the
embryos for microinjection. This method ensured successful orientation of larvae and
microinjection in the yolk sac. The larvae were easily transferred to a petridish containing embryo
water for revival.
Determination of optimum temperature for zebrafish and human BC cells:
Human cell lines are incubated at a temperature of 37°C, at which they grow and proliferate
normally. Zebrafish embryos, on the other hand, are incubated at a temperature of 28°C for the
initial five days of their life until they reach the stage where they require an external food source.
Zebrafish larvae xenografted with human cells cannot survive because of the increase in
temperature by 9°C and the cells also cannot survive a temperature which is approximately 9°C
lower than the human body temperature. So, for normal proliferation of BC cells in the fish, and
normal growth of the larvae, we incubated the larvae and the cells separately at different
temperatures. We observed that at 34°C, both the fish and the cells grew normally, without any
deformities in the fish, and normal proliferation of the BC cells. The BC cells, MCF-7, BT-474,
and MDA-MB-231, were plated in T25 flasks and the cell counts were measured after incubating
the cells at 37°C and 34°C for 72 hours. No significant differences were observed in the cell
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numbers. For zebrafish, we incubated zebrafish eggs at 28°C and 34°C and observed the embryos
after every 24 hours to determine if there were any deformities associated with the increased
temperature. We observed no deformities at 34°C but the embryos hatched at 2dpf as opposed to
3 dpf at 28°C.

Figure 21: Percent incidence of larvae incubated at 34 for a period of 4 days for different
parameters was evaluated. The larvae (n = 48) were placed in a 48 well plate and evaluated for
survival and deformities such as irregular swimming, curved body axis (bent spine), and
pericardial and yolk sac edemas.

Xenotransplant optimization
Injection cell volume:
The number of cells required per mL to get 100-150 cell in 5 nl cell suspension were
calculated to be 1x106/ml. The cell suspension was injected from the microneedle on a droplet of
oil placed on a glass slide and averaged the number of cells in 3 injections from each microneedle.
The diameter of the injection droplets was measured using a stage micrometer. The image of the
stage micrometer was captured at the same focus and magnification as the injection droplet. The
required diameter of the injection diameter to make the injection volume to be approximately 5 nL
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was 106 mm. The volume was calculated using the formula 4/3 πr3. Additionally, the number of
cells in each droplet were also manually counted from images of the injection droplet under higher
magnification (20x) using Nikon Eclipse Ti2 (Figure 22). The number of cells observed from both
methods were compared to confirm the number of cells/injection.

Figure 22: Pictomicrographs of injection droplets in oil. A) Image of four consecutive
injections acquired at 4x magnification. B) Image of injection acquired at 10 x
magnification. C) Image of two injections acquired at 20x magnification using bright field
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Injection time determination:
To determine the optimum survival of the fish and its ability to sustain the microinjection,
microinjections in the zebrafish were performed at 0, 1, and 2 dpf. At 0 dpf, the dechorionated
embryos immediately died from the injections. The larvae were injected at 2 and 3 dpf, and
observed the xenografted larvae for 6 days post injection. At 3 dpf the larvae were challenging to
inject as yolk sac was harder to penetrate with the microneedle and most of the injected larvae did
not retain the cancer cells (upon observation under the fluorescence filter). Whereas the larvae
injected at 2 dpf exhibited the ability to retain the BC cells and exhibited higher survival rate post
injection. Therefore, all subsequent microinjections were carried out at 2 dpf.
Xenotransplant assay timeline:
To study the proliferation of BC cells and to determine the effects of treatment on the larvae
post injection, the survival of the larvae post injection was observed up to 9 dpf. It was observed
that after 7 dpf, the larvae had a higher mortality rate. And as described in the previous section, 2
dpf was determined as the optimum time to inject the larvae. Hence, we decided to inject the fish
at 2 dpf and conduct our evaluation studies until 5 dpi or 7 dpf. The xenotransplantation assay
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timeline is illustrated in Figure 23.

Figure 23: Timeline of the Xenotransplant Assay

Microscopy optimization
Mounting medium:
Imaging individual larvae requires proper mounting material in order to keep the
anaesthetized larvae in place. Initially, anaesthetized larvae were inserted in warm 1% agarose gel
(not solidified) and then a drop of the agarose gel along with the larvae was sucked up and placed
on the glass slide. After imaging several larvae, autofluorescence of agarose gel was observed and
added a lot of background to the fluorescent images. Thereafter, alternate materials such as gelatin
and 2% noble agar gel were tested as the mounting gel and observed for autofluorescence. Gelatin
exhibited autofluorescence. For noble agar, a 2% noble agar gel solidified within an
immunohistology chamber was used and a groove was carved in the gel to house the anaesthetized
larvae for imaging. However, the volume of tricaine around the fish had to be optimized to ensure
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that the tricaine did not dry up from the heat emanating from the laser of the microscope lens. We
observed that noble agarose did not autofluoresce and did not interfere with the fluorescence signal
of the fish. Additionally, as suggested by Dr. Joshua Bloomekatz, we utilized electric tape to
construct an elevation on a coverslip and cut out the tape forming a rectangular space (Figure 5)
and anaesthetized larvae was placed onto the space in tricaine and covered using another coverslip.
This provided an enclosure for the larvae and provided the opportunity to enhance our field of
view of the larvae. We obtained much clearer images using this technique.
With the arrival of Nikon Eclipse Ti2, we were able to image fish in a 48 well plate using
(0.08%) low melt agarose. This was much faster, had better image quality, and we were able to
image more fish in the same period of time.

Figure 24: Elevation created using electrical tape on a coverslip for mounting anaesthetized
zebrafish larvae for imaging under fluorescence microscope. The anaesthetized larvae were stable
in this setting for 4-5 hours

Quantification of breast cancer cell proliferation via PCR
Real Time PCR in cells
For our studies, it was important to identify a gene that is expressed by BC cells but not
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constitutively expressed by normal zebrafish cells to compare the effect of treatment with
candidate compounds versus controls. As CYP1B1 is frequently expressed in human BC, we chose
this as our gene of interest. The CYP1B1 primers used were previously published (Lin et al. 2003).
In zebrafish, two types of CYP1 family genes have been characterized. cyp1a is expressed in liver
and cyp1b1, cyp1c1 and cyp1c2 are transcribed in the heart and eye in adult zebrafish. During
development, cyp1b1 is expressed maximally within 2-3 dpf, with specific expression in ocular
cells, diencephalon, and the midbrain-hindbrain boundary determined by whole-mount RNA in
situ hybridization analysis (Yin et al. 2008). So, we selected human CYP1B, specifically expressed
in the three cancer cell lines, as a marker of tumor cell expression and proliferation in zebrafish
larvae xenotransplanted with human breast cancer cells.
To detect the expression of CYP1B1 in MCF-7, BT-474, and MDA-MB-231 cells, the cells
were plated in 12 well plates at the density of 2.5x105 cells/well in 1 mL of DMEM and incubated
at 37ºC supplemented with 5% CO2. At 90% confluence, cells were detached using trypLE
EXPRESS (ThermoFisher Scientific, CA)). TrypLE was neutralized using equal volume of
DMEM and cells were centrifuged at 4000 rpm (2670 x g) for 5 minutes. Cells were counted, and
1 x106 cells were used for mRNA extraction. Cell pellet was lysed with lysis buffer (Thermo
Scientific, CA) supplemented with 2% β-mercaptoethanol. Further extraction of mRNA was
conducted using GeneJET RNA purification kit and as instructed by manufacturer (Thermo
Scientific, CA). The concentration of mRNA quantified using Nanodrop 2000, and the purity of
mRNA was determined by assessing the A260/A280 ratio and samples with values >2 were used for
further experimentation. The RNA samples were reverse-transcribed to cDNA using Taqman®
Reverse Transcription reagents (Applied Biosystems, CA): random hexamers, Multiscribe
Reverse Transcriptase, RNase inhibitor, deoxyNTP mix, 25 mM MgCl2, 10xRT buffer in 25 µL
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reaction. The temperature program used was 25 °C for 10 min, 37 °C for 60 min and 95 °C for 5
min. RT-qPCR was performed in Applied Biosystems 7200 using SYBR Green (Applied
Biosystems, Massachusetts) and the parameters used were: 95 °C for 10 min, then 40 cycles of 95
°C for 15 sec and 60 °C for 1 min, followed by 95 °C for 15 sec, 60 °C for 1 min, 95 °C for 15 sec
dissociation curve. CYP1B1 and 18S were amplified in duplicate in separate reactions on the same
plate. The fold induction of CYP1B1 mRNA in xenotransplanted zebrafish relative to non-injected
larvae were normalized to 18S given by formula =2-ΔΔCT as described by (Livak and Schmittgen,
2001), where CT was the threshold cycle indicating the fractional cycle number corresponding to
the threshold attained by the amplified CYP1B1.

Table 7: RT-qPCR primers
F: 5'-GCTGCAGTGGCTGCTCCT-3'
CYP1B1
R: 5'-CCCACGACCTGATCCAATTCT-3'
F: 5'-TGG TTA ATT CCG ATA ACG AAC GA-3'
18S
R: 5'-CGC CAC TTG TCC CTC TAA GAA-3'

RT-qPCR in zebrafish
To detect CYP1B1 in xenografted larvae and to confirm that human CYP1B1 was not
expressed in un-injected larvae, zebrafish larvae xenotransplanted with the breast cancer cells were
pooled (20 fish per vial repeated twice) at 1 dpi and 5 dpi in RNA later and stored at -80 ºC until
we performed RNA isolation on them. RNA was isolated from the larvae using TRIzol (Invitrogen,
Massachusetts), RNase-Free DNase set (Qiagen, California), and RNeasy mini kit (Qiagen,
California) using manufacturer’s protocol. The extracted RNA was then quantified on a NanoDrop
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2000 (ThermoFisher Scientific, Massachusetts) and samples were evaluated for acceptable
A260/A280 ratio. Further reverse-transcription and RT-qPCR were performed as described above.
The statistical significance from RT-qPCR results was analyzed using one-way ANOVA and
Tukey’s post hoc test where statistical significance was found to be at p ≤ 0.05. RT-qPCR results.
Human CYP1B1 was measured using RT-qPCR in the three cancer cell lines MCF-7, BT474, and MDA-MB-231, and in zebrafish xenografted with MCF-7 and MDA-MB-231 cells. Uninjected zebrafish larvae were also quantified to detect any expression. Expression of CYP1B1
was detected in all three cell lines and the xenograft larvae, but not detected in un-injected larvae.
To our knowledge, the expression of a gene as a quantitative method to determine the effect
of anti-cancer compounds has not been done before and represents an additional method that can
be used to validate the effect of treatment. Although, high concentration of mRNA from zebrafish
xenografts could not be extracted, the expression of CYP1B1 in the breast cancer cell lines and
the xenografted fish was detected.
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